10363983	11545	Adams J	Proteasome inhibitors: a novel class of potent and effective antitumor agents.	Cancer research	1999	234
12440774	11545	Hassa PO	The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders.	Cellular and molecular life sciences 	2002	97
14709739	11545	Calabrese CR	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.	Journal of the National Cancer Institute	2004	101
15829966	11545	Bryant HE	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.	Nature	2005	911
17363489	11545	Thomas HD	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.	Molecular cancer therapeutics	2007	59
17919258	11545	Pacher P	Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.	Cardiovascular drug reviews	2007	64
18559613	11545	Evers B	Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.	Clinical cancer research 	2008	67
18971340	11545	Rottenberg S	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.	Proceedings of the National Academy of Sciences of the United States of America	2008	190
20124459	11545	Williamson CT	ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.	Molecular cancer therapeutics	2010	56
20228137	11545	Algire C	Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.	Endocrine-related cancer	2010	60
20530711	11545	Löser DA	Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.	Molecular cancer therapeutics	2010	44
20739657	11545	Weston VJ	The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.	Blood	2010	79
20924112	11545	Chan N	Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.	Cancer research	2010	41
21459330	11545	Bai P	PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation.	Cell metabolism	2011	152
21504625	11545	Yuan Y	Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.	Journal of hematology and oncology	2011	39
21681448	11545	Speyer CL	Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.	Breast cancer research and treatment	2012	35
22158865	11545	Patel AG	Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.	The Journal of biological chemistry	2012	32
22287547	11545	Brenner JC	PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.	Cancer research	2012	56
23582862	11545	Xu W	Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.	Biomaterials	2013	30
24016618	11545	Skor MN	Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.	Clinical cancer research 	2013	33
24885920	11545	Zhang L	microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer.	Molecular cancer	2014	22
25629353	11545	Howard SM	DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining.	PLoS genetics	2015	31
25642963	11545	Ceccaldi R	Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.	Nature	2015	79
25995442	11545	Liu G	Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.	Journal of the National Cancer Institute	2015	18
26217019	11545	Hopkins TA	Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.	Molecular cancer research 	2015	22
27225932	11545	Vazquez BN	SIRT7 promotes genome integrity and modulates non-homologous end joining DNA repair.	The EMBO journal	2016	17
19150350	11576	Yamashita T	EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.	Gastroenterology	2009	274
22974708	11576	Villanueva A	Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice.	Gastroenterology	2012	62
25346390	11576	Uriarte I	Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development.	International journal of cancer	2015	16
1549603	11622	Zhang Y	A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure.	Proceedings of the National Academy of Sciences of the United States of America	1992	235
7732381	11622	Fernandez-Salguero P	Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor.	Science	1995	196
8806883	11622	Fernandez-Salguero PM	Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity.	Toxicology and applied pharmacology	1996	121
10639156	11622	Shimizu Y	Benzoapyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor.	Proceedings of the National Academy of Sciences of the United States of America	2000	94
15028720	11622	Nebert DW	Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer.	The Journal of biological chemistry	2004	199
15790560	11622	Miao W	Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes.	The Journal of biological chemistry	2005	80
17535977	11622	McMillan BJ	The aryl hydrocarbon receptor sans xenobiotics: endogenous function in genetic model systems.	Molecular pharmacology	2007	60
18697742	11622	Baglole CJ	The aryl hydrocarbon receptor attenuates tobacco smoke-induced cyclooxygenase-2 and prostaglandin production in lung fibroblasts through regulation of the NF-kappaB family member RelB.	The Journal of biological chemistry	2008	54
19651607	11622	Kawajiri K	Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands.	Proceedings of the National Academy of Sciences of the United States of America	2009	53
19996281	11622	Fan Y	The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis.	Cancer research	2010	49
23771949	11622	Safe S	Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.	Toxicological sciences 	2013	45
24930766	11622	Bessede A	Aryl hydrocarbon receptor control of a disease tolerance defence pathway.	Nature	2014	81
10802656	11651	Holland EC	Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.	Nature genetics	2000	213
11485901	11651	Sun M	AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.	The American journal of pathology	2001	102
12086888	11651	Orsulic S	Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.	Cancer cell	2002	102
12097282	11651	Lokker NA	Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.	Cancer research	2002	82
12237475	11651	Condorelli G	Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice.	Proceedings of the National Academy of Sciences of the United States of America	2002	122
12649187	11651	Blaskovich MA	Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.	Cancer research	2003	162
12799464	11651	Majumder PK	Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.	Proceedings of the National Academy of Sciences of the United States of America	2003	99
14760102	11651	Ciardiello F	Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.	Clinical cancer research 	2004	72
15029198	11651	Wendel HG	Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.	Nature	2004	273
15126356	11651	Hutchinson JN	Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion.	Cancer research	2004	77
15485899	11651	Lai KM	Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy.	Molecular and cellular biology	2004	108
15705789	11651	Hammerman PS	Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival.	Blood	2005	73
16007214	11651	Xu Q	Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways.	Oncogene	2005	139
16169463	11651	Hay N	The Akt-mTOR tango and its relevance to cancer.	Cancer cell	2005	201
16288285	11651	Testa JR	AKT signaling in normal and malignant cells.	Oncogene	2005	77
16288295	11651	Cheng JQ	The Akt/PKB pathway: molecular target for cancer drug discovery.	Oncogene	2005	125
16397234	11651	Sunters A	Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.	Cancer research	2006	75
16446424	11651	Furuya F	Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.	Proceedings of the National Academy of Sciences of the United States of America	2006	63
16632640	11651	French KJ	Antitumor activity of sphingosine kinase inhibitors.	The Journal of pharmacology and experimental therapeutics	2006	76
16778075	11651	Chen ML	The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.	Genes and development	2006	95
17045205	11651	Skeen JE	Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner.	Cancer cell	2006	83
17082322	11651	Sin SH	Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.	Blood	2007	65
17210696	11651	Maroulakou IG	Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.	Cancer research	2007	103
17290308	11651	Zhang H	PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.	The Journal of clinical investigation	2007	116
17460049	11651	Ju X	Akt1 governs breast cancer progression in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2007	80
17891174	11651	Ma S	CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.	Oncogene	2008	198
17997386	11651	Marone R	Targeting phosphoinositide 3-kinase: moving towards therapy.	Biochimica et biophysica acta	2008	156
18182616	11651	Baba M	Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.	Journal of the National Cancer Institute	2008	76
18292230	11651	Dickey CA	Akt and CHIP coregulate tau degradation through coordinated interactions.	Proceedings of the National Academy of Sciences of the United States of America	2008	64
18354169	11651	Jacobs SR	Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways.	Journal of immunology	2008	156
18617895	11651	Yuan M	Yes-associated protein (YAP) functions as a tumor suppressor in breast.	Cell death and differentiation	2008	70
18794877	11651	Endersby R	PTEN signaling in brain: neuropathology and tumorigenesis.	Oncogene	2008	65
18802038	11651	Eyler CE	Brain cancer stem cells display preferential sensitivity to Akt inhibition.	Stem cells	2008	81
19138937	11651	Moore T	Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues.	Cancer prevention research	2008	52
19491266	11651	Dillon RL	Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression.	Cancer research	2009	53
19609947	11651	Bai D	Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt.	International journal of cancer	2009	51
19699171	11651	Androulidaki A	The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs.	Immunity	2009	170
19850877	11651	Hasumi Y	Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.	Proceedings of the National Academy of Sciences of the United States of America	2009	78
19965668	11651	Peng C	PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.	Blood	2010	43
20008787	11651	Kharas MG	Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.	Blood	2010	81
20068149	11651	Novosyadlyy R	Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.	Cancer research	2010	89
20074638	11651	Venkatesan B	WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death.	Cellular signalling	2010	43
20198336	11651	Zhang J	miR-221/222 promote malignant progression of glioma through activation of the Akt pathway.	International journal of oncology	2010	44
20351312	11651	Krawczyk CM	Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation.	Blood	2010	169
20354168	11651	Juntilla MM	AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species.	Blood	2010	79
20424120	11651	Dillon RL	Distinct biological roles for the akt family in mammary tumor progression.	Cancer research	2010	57
20479243	11651	Li J	Activation of dormant ovarian follicles to generate mature eggs.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
20530718	11651	Fritz V	Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.	Molecular cancer therapeutics	2010	43
20553984	11651	Mohanty C	The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation.	Biomaterials	2010	51
20708588	11651	Ashton GH	Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling.	Developmental cell	2010	54
20811583	11651	Wu Z	Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors.	Genes and cancer	2010	64
20843817	11651	Choi SS	Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway.	The Journal of biological chemistry	2010	41
20951698	11651	Lombardo Y	Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.	Gastroenterology	2011	46
20980833	11651	Vucicevic L	Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.	Autophagy	2011	37
21350002	11651	Boreddy SR	Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway.	Clinical cancer research 	2011	44
21387290	11651	Urakawa H	Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo.	International journal of cancer	2012	32
21670491	11651	Hart JR	Phosphorylation of AKT: a mutational analysis.	Oncotarget	2011	37
21744257	11651	Ogunwobi OO	Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways.	Clinical and experimental metastasis	2011	39
21775285	11651	Sundaresan NR	The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy.	Science signaling	2011	75
21915300	11651	Jijiwa M	CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway.	PloS one	2011	42
21993994	11651	Ho C	AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.	Hepatology	2012	49
22308314	11651	Conley SJ	Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.	Proceedings of the National Academy of Sciences of the United States of America	2012	142
22322096	11651	Stokes MP	PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS.	Molecular and cellular proteomics 	2012	31
22355272	11651	Mukherjee B	The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.	Neoplasia	2012	50
22446186	11651	Selvaraj S	Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling.	The Journal of clinical investigation	2012	32
22505453	11651	Nacerddine K	Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.	The Journal of clinical investigation	2012	41
22647600	11651	Arranz A	Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization.	Proceedings of the National Academy of Sciences of the United States of America	2012	85
22689977	11651	Jo H	Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death.	Proceedings of the National Academy of Sciences of the United States of America	2012	36
22797301	11651	Fan B	Cholangiocarcinomas can originate from hepatocytes in mice.	The Journal of clinical investigation	2012	79
22826565	11651	Zeng Z	Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.	Blood	2012	35
23085755	11651	Huang WH	Mesenchymal stem cells promote growth and angiogenesis of tumors in mice.	Oncogene	2013	37
23125220	11651	Zhang LY	MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN.	Carcinogenesis	2013	47
23224399	11651	Garrett JT	Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.	Clinical cancer research 	2013	26
23335250	11651	Osuka S	IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells.	Stem cells	2013	29
24067903	11651	Shukla S	Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.	Carcinogenesis	2014	21
24335962	11651	Chin YR	Targeting Akt3 signaling in triple-negative breast cancer.	Cancer research	2014	21
24488013	11651	Miao H	EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties.	Oncogene	2015	26
24587182	11651	Di Martino MT	In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.	PloS one	2014	22
24651542	11651	Ito K	Metabolic requirements for the maintenance of self-renewing stem cells.	Nature reviews. Molecular cell biology	2014	132
24670654	11651	Liu P	Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus.	Nature	2014	64
24825302	11651	Chang RM	MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase.	Hepatology	2014	31
24957076	11651	Fuentes-Mattei E	Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.	Journal of the National Cancer Institute	2014	28
25330770	11651	Liu JC	Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.	EMBO molecular medicine	2014	22
25428912	11651	Chen H	Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A.	Oncotarget	2014	30
25432172	11651	Crompton JG	Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.	Cancer research	2015	38
25446031	11651	Busada JT	Retinoic acid regulates Kit translation during spermatogonial differentiation in the mouse.	Developmental biology	2015	15
25617127	11651	Chen CL	Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation.	Biomaterials	2015	35
26107252	11651	Wilson JE	Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt.	Nature medicine	2015	26
26136189	11651	Chen JA	Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved.	Journal of cachexia, sarcopenia and muscle	2015	16
26194913	11651	Yang WJ	Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis.	EMBO molecular medicine	2015	21
26224873	11651	Arqués O	Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.	Clinical cancer research 	2016	12
26476289	11651	Li L	Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.	Journal of hepatology	2016	11
26589417	11651	Li WF	Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.	Tumour biology 	2016	11
26848154	11651	Correia-Melo C	Mitochondria are required for pro-ageing features of the senescent phenotype.	The EMBO journal	2016	29
26857837	11651	Hu J	Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.	Scientific reports	2016	11
27153497	11651	Masri S	Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis.	Cell	2016	17
27524110	11651	Ratsimandresy RA	The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway.	Cellular and molecular immunology	2017	11
15917471	11670	Pearce DJ	Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.	Stem cells	2005	82
18829980	11670	Kallifatidis G	Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling.	Gut	2009	60
19544409	11670	Burger PE	High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells.	Stem cells	2009	47
20073073	11670	Clay MR	Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase.	Head and neck	2010	124
20164446	11670	Rasheed ZA	Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.	Journal of the National Cancer Institute	2010	129
20309879	11670	Wang L	Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity.	International journal of cancer	2011	35
20959469	11670	Todaro M	Tumorigenic and metastatic activity of human thyroid cancer stem cells.	Cancer research	2010	54
21085683	11670	Awad O	High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.	PloS one	2010	50
21498635	11670	Silva IA	Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.	Cancer research	2011	110
22020330	11670	Canino C	SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.	Oncogene	2012	31
22023707	11670	Wei L	Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.	Breast cancer research 	2011	36
22262762	11670	Gerber JM	A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.	Blood	2012	60
23088371	11670	Shehata M	Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland.	Breast cancer research 	2012	77
23650391	11670	Mao P	Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3.	Proceedings of the National Academy of Sciences of the United States of America	2013	109
18923524	11682	Chen Y	Oncogenic mutations of ALK kinase in neuroblastoma.	Nature	2008	208
18923525	11682	George RE	Activating mutations in ALK provide a therapeutic target in neuroblastoma.	Nature	2008	211
19064915	11682	Soda M	A mouse model for EML4-ALK-positive lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2008	121
22347464	11682	Togashi Y	KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.	PloS one	2012	51
22764207	11682	Heukamp LC	Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.	Science translational medicine	2012	32
22789543	11682	Berry T	The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.	Cancer cell	2012	64
25205428	11682	Kodama T	Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.	Cancer chemotherapy and pharmacology	2014	22
25337876	11682	Maddalo D	In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.	Nature	2014	96
25456124	11682	Blasco RB	Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology.	Cell reports	2014	38
26144315	11682	Zou HY	PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.	Cancer cell	2015	37
26444240	11682	Wiesner T	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.	Nature	2015	20
12414638	11747	Ran S	Increased exposure of anionic phospholipids on the surface of tumor blood vessels.	Cancer research	2002	85
19401262	11747	Lima LG	Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner.	Cancer letters	2009	49
24525732	11747	Kang SU	Nonthermal plasma induces head and neck cancer cell death: the potential involvement of mitogen-activated protein kinase-dependent mitochondrial reactive oxygen species.	Cell death and disease	2014	29
1350108	11789	Su LK	Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.	Science	1992	381
8242739	11789	Dietrich WF	Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse.	Cell	1993	149
9311916	11789	Shibata H	Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene.	Science	1997	134
9506519	11789	Takaku K	Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes.	Cell	1998	118
11283620	11789	Fodde R	Mutations in the APC tumour suppressor gene cause chromosomal instability.	Nature cell biology	2001	184
12119409	11789	Kucherlapati M	Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression.	Proceedings of the National Academy of Sciences of the United States of America	2002	87
12130785	11789	Millar CB	Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice.	Science	2002	97
14758356	11789	Gupta RA	Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth.	Nature medicine	2004	72
15563600	11789	Colnot S	Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas.	Proceedings of the National Academy of Sciences of the United States of America	2004	75
15716339	11789	Andreu P	Crypt-restricted proliferation and commitment to the Paneth cell lineage following Apc loss in the mouse intestine.	Development	2005	80
16174748	11789	Yamada Y	Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2005	74
16880406	11789	Myung SJ	15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2006	87
16959882	11789	Sansom OJ	Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2006	62
17047044	11789	Muñoz NM	Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.	Cancer research	2006	65
17377531	11789	Sansom OJ	Myc deletion rescues Apc deficiency in the small intestine.	Nature	2007	201
17671182	11789	Ghaleb AM	Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis.	Cancer research	2007	59
17942902	11789	Hinoi T	Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation.	Cancer research	2007	99
18055444	11789	May R	Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice.	Stem cells	2008	108
18538487	11789	McCart AE	Apc mice: models, modifiers and mutants.	Pathology, research and practice	2008	57
19263594	11789	Taketo MM	Mouse models of colon cancer.	Gastroenterology	2009	72
20473309	11789	Lee SH	ERK activation drives intestinal tumorigenesis in Apc(min/+) mice.	Nature medicine	2010	65
20696900	11789	Poulogiannis G	PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
21876161	11789	Goodwin AC	Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	46
21889923	11789	Sato T	Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.	Gastroenterology	2011	285
21982234	11789	Luis TC	Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion.	Cell stem cell	2011	90
24264992	11789	Vermeulen L	Defining stem cell dynamics in models of intestinal tumor initiation.	Science	2013	78
21498569	11793	Takamura A	Autophagy-deficient mice develop multiple liver tumors.	Genes and development	2011	258
21746920	11793	Parkhitko A	Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.	Proceedings of the National Academy of Sciences of the United States of America	2011	73
21810913	11793	Noman MZ	Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression.	Cancer research	2011	38
22847423	11793	Wang Y	Autophagic activity dictates the cellular response to oncogenic RAS.	Proceedings of the National Academy of Sciences of the United States of America	2012	38
23181220	11793	Kongara S	The interplay between autophagy and ROS in tumorigenesis.	Frontiers in oncology	2012	35
23461901	11793	Selvakumaran M	Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy.	Clinical cancer research 	2013	35
24305049	11793	Rosenfeldt MT	p53 status determines the role of autophagy in pancreatic tumour development.	Nature	2013	132
24445999	11793	Rao S	A dual role for autophagy in a murine model of lung cancer.	Nature communications	2014	77
24815875	11793	Ni HM	Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy.	Journal of hepatology	2014	28
25526090	11793	Tian Y	Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis.	Cell death and differentiation	2015	18
25550510	11793	López-Vicario C	Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides.	Proceedings of the National Academy of Sciences of the United States of America	2015	16
26649827	11793	Kimmey JM	Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection.	Nature	2015	33
26749442	11793	Akoumianaki T	Aspergillus Cell Wall Melanin Blocks LC3-Associated Phagocytosis to Promote Pathogenicity.	Cell host and microbe	2016	12
12885482	11799	Kim PJ	Survivin and molecular pathogenesis of colorectal cancer.	Lancet	2003	78
17804712	11799	Nakahara T	YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.	Cancer research	2007	113
18593936	11799	Chadalapaka G	Curcumin decreases specificity protein expression in bladder cancer cells.	Cancer research	2008	57
18851829	11799	Wang RH	Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.	Molecular cell	2008	111
20538607	11799	Jutooru I	Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation.	The Journal of biological chemistry	2010	63
20606648	11799	Chen Y	Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.	Molecular therapy 	2010	121
22572880	11799	Arora R	Survivin is a therapeutic target in Merkel cell carcinoma.	Science translational medicine	2012	37
24440709	11799	Rauch A	Survivin and YM155: how faithful is the liaison?	Biochimica et biophysica acta	2014	34
24621249	11799	Castle JC	Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.	BMC genomics	2014	24
24913717	11799	Chandra D	STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer.	Cancer immunology research	2014	24
25900794	11799	Hu Y	miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.	Breast cancer research and treatment	2015	17
26148234	11799	Hagenbuchner J	BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma.	Oncogene	2016	10
7724580	11835	Greenberg NM	Prostate cancer in a transgenic mouse.	Proceedings of the National Academy of Sciences of the United States of America	1995	332
12370412	11835	Yeh S	Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues.	Proceedings of the National Academy of Sciences of the United States of America	2002	136
12692788	11835	Kaplan-Lefko PJ	Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.	The Prostate	2003	138
15107499	11835	Chang C	Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells.	Proceedings of the National Academy of Sciences of the United States of America	2004	101
16140970	11835	Zhou HJ	SRC-3 is required for prostate cancer cell proliferation and survival.	Cancer research	2005	77
16973730	11835	Wang RS	Androgen receptor in sertoli cell is essential for germ cell nursery and junctional complex formation in mouse testes.	Endocrinology	2006	63
17334372	11835	Yang Z	ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor.	Nature medicine	2007	56
17406000	11835	Miyamoto H	Promotion of bladder cancer development and progression by androgen receptor signals.	Journal of the National Cancer Institute	2007	96
17652515	11835	Wu CT	Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor.	Proceedings of the National Academy of Sciences of the United States of America	2007	71
18639551	11835	Ma WL	Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma.	Gastroenterology	2008	55
19176467	11835	Wang RS	Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice.	Endocrine reviews	2009	63
22438320	11835	Germann M	Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer.	Stem cells	2012	32
23499463	11835	Hsu JW	Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.	The American journal of pathology	2013	25
23817021	11835	Chen Y	ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.	Nature medicine	2013	80
23873027	11835	Chang C	Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver.	Oncogene	2014	37
23878190	11835	Fang LY	Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling.	Cancer research	2013	28
24130167	11835	Akinyeke T	Metformin targets c-MYC oncogene to prevent prostate cancer.	Carcinogenesis	2013	29
24297183	11835	Sun F	Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors.	The Journal of biological chemistry	2014	30
25822367	11835	Malik R	Targeting the MLL complex in castration-resistant prostate cancer.	Nature medicine	2015	29
27232975	11835	DeRita RM	c-Src, Insulin-Like Growth Factor I Receptor, G-Protein-Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes.	Journal of cellular biochemistry	2017	5
28059767	11835	Ku SY	Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.	Science	2017	11
15313928	11846	Rodriguez PC	Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.	Cancer research	2004	215
20804550	11846	Veltman JD	COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.	BMC cancer	2010	52
21810604	11846	Sharda DR	Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase.	Journal of immunology	2011	37
22926062	11846	Tongu M	Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.	Cancer immunology, immunotherapy 	2013	32
25201986	11846	Duque-Correa MA	Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
27043409	11846	Monticelli LA	Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation.	Nature immunology	2016	11
18794355	11848	Kong W	MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA.	Molecular and cellular biology	2008	217
21266354	11848	Timpson P	Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.	Cancer research	2011	40
23358651	11848	Konstantinidou G	RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.	Cancer discovery	2013	33
24343302	11848	Zhang C	Tumour-associated mutant p53 drives the Warburg effect.	Nature communications	2013	52
25341788	11848	Acton SE	Dendritic cells control fibroblastic reticular network tension and lymph node expansion.	Nature	2014	31
26446958	11848	Le Gal K	Antioxidants can increase melanoma metastasis in mice.	Science translational medicine	2015	53
26690702	11848	Yu J	Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.	The Journal of clinical investigation	2016	12
8689683	11920	Barlow C	Atm-deficient mice: a paradigm of ataxia telangiectasia.	Cell	1996	392
8843194	11920	Xu Y	Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma.	Genes and development	1996	224
11459832	11920	Lin WC	Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation.	Genes and development	2001	134
12192050	11920	Hirao A	Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner.	Molecular and cellular biology	2002	97
12540856	11920	Wong KK	Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing.	Nature	2003	98
15640358	11920	Di Giacomo M	Distinct DNA-damage-dependent and -independent responses drive the loss of oocytes in recombination-defective mouse mutants.	Proceedings of the National Academy of Sciences of the United States of America	2005	73
17136093	11920	Bartkova J	Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints.	Nature	2006	560
17431503	11920	Kennedy RD	Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.	The Journal of clinical investigation	2007	57
18097482	11920	Maclean KH	Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis.	The Journal of clinical investigation	2008	108
20160076	11920	Alexander A	ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS.	Proceedings of the National Academy of Sciences of the United States of America	2010	168
20663956	11920	Li M	The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2010	67
21368836	11920	Deriano L	The RAG2 C terminus suppresses genomic instability and lymphomagenesis.	Nature	2011	38
22002603	11920	Lange J	ATM controls meiotic double-strand-break formation.	Nature	2011	66
22079189	11920	Ditch S	The ATM protein kinase and cellular redox signaling: beyond the DNA damage response.	Trends in biochemical sciences	2012	85
22144182	11920	Valentin-Vega YA	Mitochondrial dysfunction in ataxia-telangiectasia.	Blood	2012	84
22173583	11920	Kanai R	Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.	Journal of the National Cancer Institute	2012	34
22797809	11920	Okuno Y	Pathological neoangiogenesis depends on oxidative stress regulation by ATM.	Nature medicine	2012	40
22869595	11920	Daniel JA	Loss of ATM kinase activity leads to embryonic lethality in mice.	The Journal of cell biology	2012	37
22869596	11920	Yamamoto K	Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice.	The Journal of cell biology	2012	37
24366691	11920	Gil del Alcazar CR	Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.	Clinical cancer research 	2014	27
25079327	11920	Santos MA	DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier.	Nature	2014	33
25692705	11920	Härtlova A	DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity.	Immunity	2015	56
25818648	11920	Jiang W	Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during nonhomologous end-joining.	Molecular cell	2015	16
27732836	11920	Fang EF	NAD&lt;sup&gt;+&lt;/sup&gt; Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair.	Cell metabolism	2016	12
11163212	12018	Lindsten T	The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues.	Molecular cell	2000	376
12244308	12018	Rathmell JC	Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis.	Nature immunology	2002	98
12624178	12018	Scorrano L	BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis.	Science	2003	339
15680329	12018	Lum JJ	Growth factor regulation of autophagy and cell survival in the absence of apoptosis.	Cell	2005	423
16055554	12018	Takeuchi O	Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease.	Proceedings of the National Academy of Sciences of the United States of America	2005	78
17097561	12018	van Delft MF	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.	Cancer cell	2006	414
17676052	12018	Kirsch DG	A spatially and temporally restricted mouse model of soft tissue sarcoma.	Nature medicine	2007	113
20019247	12018	Kirsch DG	p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis.	Science	2010	79
8183579	12028	Miyashita T	Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.	Oncogene	1994	308
11175253	12028	Korsmeyer SJ	Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c.	Cell death and differentiation	2000	186
12750523	12028	Garcia-Barros M	Tumor response to radiotherapy regulated by endothelial cell apoptosis.	Science	2003	285
12952892	12028	Shibue T	Integral role of Noxa in p53-mediated apoptotic response.	Genes and development	2003	79
16505490	12028	Malhi H	Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis.	The Journal of biological chemistry	2006	163
16645094	12028	Hetz C	Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha.	Science	2006	185
16862141	12028	Strom E	Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation.	Nature chemical biology	2006	104
17079463	12028	Chen D	Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.	Cancer research	2006	91
17404107	12028	Mohammad RM	Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.	Clinical cancer research 	2007	58
17671092	12028	George NM	A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax.	Genes and development	2007	58
18056705	12028	Okoshi R	Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress.	The Journal of biological chemistry	2008	80
21911424	12028	Josefsson EC	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets.	The Journal of experimental medicine	2011	38
2250704	12043	Strasser A	Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.	Nature	1990	206
2649247	12043	McDonnell TJ	bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.	Cell	1989	211
10197582	12043	Korsmeyer SJ	BCL-2 gene family and the regulation of programmed cell death.	Cancer research	1999	119
12086670	12043	McGill GG	Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability.	Cell	2002	166
12086865	12043	Schmitt CA	Dissecting p53 tumor suppressor functions in vivo.	Cancer cell	2002	141
12393617	12043	Cooper MA	In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells.	Blood	2002	113
14662907	12043	Kondrack RM	Interleukin 7 regulates the survival and generation of memory CD4 cells.	The Journal of experimental medicine	2003	147
17440100	12043	Kunnumakkara AB	Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.	Cancer research	2007	139
17632527	12043	Dierks C	Essential role of stromally induced hedgehog signaling in B-cell malignancies.	Nature medicine	2007	99
17656095	12043	Bommer GT	p53-mediated activation of miRNA34 candidate tumor-suppressor genes.	Current biology 	2007	325
18000061	12043	Stathopoulos GT	Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2007	61
18381954	12043	Kunnumakkara AB	Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products.	Clinical cancer research 	2008	58
18931683	12043	Bonci D	The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.	Nature medicine	2008	289
19137012	12043	Beverly LJ	MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family.	Oncogene	2009	45
19276343	12043	Thangaraju M	GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon.	Cancer research	2009	72
20473297	12043	Sotiropoulou PA	Bcl-2 and accelerated DNA repair mediates resistance of hair follicle bulge stem cells to DNA-damage-induced cell death.	Nature cell biology	2010	67
21768359	12043	Oakes SR	Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.	Proceedings of the National Academy of Sciences of the United States of America	2012	45
22258505	12043	He C	Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis.	Nature	2012	245
23341542	12043	Vandenberg CJ	ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.	Blood	2013	52
24346116	12043	Pan R	Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.	Cancer discovery	2014	75
24786774	12043	Fresquet V	Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.	Blood	2014	23
25952548	12043	Delbridge AR	The BCL-2 protein family, BH3-mimetics and cancer therapy.	Cell death and differentiation	2015	51
25994220	12043	Shi C	Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer.	Gut	2016	16
26366712	12043	Zhang J	Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.	Nature medicine	2015	26
26657143	12043	Chang J	Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice.	Nature medicine	2016	68
7926765	12151	van der Lugt NM	Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene.	Genes and development	1994	202
9923679	12151	Jacobs JJ	The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus.	Nature	1999	471
10541554	12151	Jacobs JJ	Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.	Genes and development	1999	172
12589020	12151	Voncken JW	Rnf2 (Ring1b) deficiency causes gastrulation arrest and cell cycle inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2003	89
15029199	12151	Leung C	Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas.	Nature	2004	159
15964995	12151	Bruggeman SW	Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice.	Genes and development	2005	109
16214129	12151	Zhu W	Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo.	Experimental and molecular pathology	2006	90
17673212	12151	Chiba T	Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation.	Gastroenterology	2007	57
17936558	12151	Bruggeman SW	Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.	Cancer cell	2007	94
18697930	12151	Dovey JS	Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion.	Proceedings of the National Academy of Sciences of the United States of America	2008	56
19404261	12151	Liu J	Bmi1 regulates mitochondrial function and the DNA damage response pathway.	Nature	2009	163
19811902	12151	Wilson A	Balancing dormant and self-renewing hematopoietic stem cells.	Current opinion in genetics and development	2009	64
20484027	12151	Meyer MJ	CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer.	Cancer research	2010	56
21551099	12151	Asp P	Genome-wide remodeling of the epigenetic landscape during myogenic differentiation.	Proceedings of the National Academy of Sciences of the United States of America	2011	106
21624810	12151	Smith LL	Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells.	Cell stem cell	2011	38
23733246	12151	Peruzzi P	MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells.	Neuro-oncology	2013	39
24092377	12151	Luo Y	Rapamycin enhances long-term hematopoietic reconstitution of ex vivo expanded mouse hematopoietic stem cells by inhibiting senescence.	Transplantation	2014	21
24219349	12151	Yu X	miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1.	Stem cells and development	2014	26
24911876	12151	Lu R	Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway.	Oncogenesis	2014	21
25348805	12151	Paranjape AN	Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.	BMC cancer	2014	27
26942853	12151	Zhou Y	Bmi1 Is a Key Epigenetic Barrier to Direct Cardiac Reprogramming.	Cell stem cell	2016	17
8674108	12189	Hakem R	The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.	Cell	1996	153
9171368	12189	Ludwig T	Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.	Genes and development	1997	127
10319859	12189	Xu X	Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.	Nature genetics	1999	197
10549283	12189	Moynahan ME	Brca1 controls homology-directed DNA repair.	Molecular cell	1999	306
10843985	12189	Bhattacharyya A	The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.	The Journal of biological chemistry	2000	155
11431698	12189	Xu X	Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.	Nature genetics	2001	88
11934988	12189	Celeste A	Genomic instability in mice lacking histone H2AX.	Science	2002	411
12533509	12189	Cao L	Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform.	Genes and development	2003	102
17138902	12189	Poole AJ	Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.	Science	2006	83
17626182	12189	Liu X	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	110
17626183	12189	Rottenberg S	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	67
18230721	12189	Liu S	BRCA1 regulates human mammary stem/progenitor cell fate.	Proceedings of the National Academy of Sciences of the United States of America	2008	154
18375767	12189	Tan-Wong SM	Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene.	Proceedings of the National Academy of Sciences of the United States of America	2008	56
18451150	12189	Shafee N	Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.	Cancer research	2008	95
19716796	12189	Cao L	A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.	Molecular cell	2009	93
20804975	12189	Molyneux G	BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.	Cell stem cell	2010	200
21765473	12189	Regan JL	c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.	Oncogene	2012	34
21901007	12189	Zhu Q	BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.	Nature	2011	124
22034435	12189	Shakya R	BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.	Science	2011	79
22172724	12189	Drost R	BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.	Cancer cell	2011	57
22445484	12189	Bunting SF	BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair.	Molecular cell	2012	82
22841781	12189	Hua G	Crypt base columnar stem cells in small intestines of mice are radioresistant.	Gastroenterology	2012	61
22915751	12189	Juvekar A	Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.	Cancer discovery	2012	72
23103855	12189	Jaspers JE	Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.	Cancer discovery	2013	70
23857982	12189	Gorrini C	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.	The Journal of experimental medicine	2013	36
24842372	12189	Polato F	CtIP-mediated resection is essential for viability and can operate independently of BRCA1.	The Journal of experimental medicine	2014	20
27241552	12189	Sigl V	RANKL/RANK control Brca1 mutation-driven mammary tumors.	Cell research	2016	11
27322743	12189	Nolan E	RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.	Nature medicine	2016	16
9126738	12190	Sharan SK	Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2.	Nature	1997	197
11239455	12190	Moynahan ME	BRCA2 is required for homology-directed repair of chromosomal breaks.	Molecular cell	2001	237
11694875	12190	Jonkers J	Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.	Nature genetics	2001	369
12893777	12190	Houghtaling S	Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice.	Genes and development	2003	94
15375219	12190	Daniels MJ	Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2.	Science	2004	78
21056012	12190	Skoulidis F	Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.	Cancer cell	2010	49
21076401	12190	Badie S	BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.	Nature structural and molecular biology	2010	55
21183737	12190	Drew Y	Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.	Journal of the National Cancer Institute	2011	65
22493542	12190	Herreros-Villanueva M	Mouse models of pancreatic cancer.	World journal of gastroenterology	2012	34
26584049	12190	García-Rubio ML	The Fanconi Anemia Pathway Protects Genome Integrity from R-loops.	PLoS genetics	2015	24
26916719	12190	Maresch R	Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice.	Nature communications	2016	12
11544272	12317	Cheng WF	Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.	The Journal of clinical investigation	2001	89
17187072	12317	Obeid M	Calreticulin exposure dictates the immunogenicity of cancer cell death.	Nature medicine	2007	448
19881547	12317	Tesniere A	Immunogenic death of colon cancer cells treated with oxaliplatin.	Oncogene	2010	123
23019653	12317	Senovilla L	An immunosurveillance mechanism controls cancer cell ploidy.	Science	2012	95
26608331	12317	Marty C	Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.	Blood	2016	27
26668133	12317	Chachoua I	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.	Blood	2016	31
26951227	12317	Elf S	Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.	Cancer discovery	2016	17
9646173	12362	Dinarello CA	Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist.	International reviews of immunology	1998	107
11104820	12362	Chang HY	Proteases for cell suicide: functions and regulation of caspases.	Microbiology and molecular biology reviews 	2000	94
16984919	12362	Amer A	Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf.	The Journal of biological chemistry	2006	170
18474815	12362	Abbate A	Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.	Circulation	2008	75
19362020	12362	Allen IC	The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA.	Immunity	2009	283
20226691	12362	Dupaul-Chicoine J	Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases.	Immunity	2010	141
20385749	12362	Allen IC	The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer.	The Journal of experimental medicine	2010	164
20679532	12362	Ulland TK	Cutting edge: mutation of Francisella tularensis mviN leads to increased macrophage absent in melanoma 2 inflammasome activation and a loss of virulence.	Journal of immunology	2010	42
20855874	12362	Zaki MH	IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation.	Journal of immunology	2010	71
21118981	12362	Hu B	Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4.	Proceedings of the National Academy of Sciences of the United States of America	2010	88
21219188	12362	Davis BK	The inflammasome NLRs in immunity, inflammation, and associated diseases.	Annual review of immunology	2011	324
22234969	12362	Yan W	High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases.	Hepatology	2012	56
23202296	12362	Bruchard M	Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.	Nature medicine	2013	118
23630357	12362	Shenderov K	Cord factor and peptidoglycan recapitulate the Th17-promoting adjuvant activity of mycobacteria through mincle/CARD9 signaling and the inflammasome.	Journal of immunology	2013	29
23707339	12362	Aachoui Y	Inflammasome-mediated pyroptotic and apoptotic cell death, and defense against infection.	Current opinion in microbiology	2013	32
24031018	12362	Hagar JA	Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock.	Science	2013	144
24799700	12362	Philip NH	Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-κB and MAPK signaling.	Proceedings of the National Academy of Sciences of the United States of America	2014	41
25075770	12362	Shahzad K	Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy.	Kidney international	2015	35
26008898	12362	Kim ML	Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β.	The Journal of experimental medicine	2015	16
26375003	12362	Shi J	Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death.	Nature	2015	142
9512515	12367	Woo M	Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes.	Genes and development	1998	122
9545256	12367	Jänicke RU	Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis.	The Journal of biological chemistry	1998	324
16166336	12367	Conaway CC	Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice.	Cancer research	2005	73
16936720	12367	Putt KS	Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.	Nature chemical biology	2006	66
17911264	12367	Gironella M	Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2007	167
18037988	12367	Suliman HB	The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy.	The Journal of clinical investigation	2007	81
18357341	12367	Breart B	Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.	The Journal of clinical investigation	2008	86
18695136	12367	Ottewell PD	Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.	Journal of the National Cancer Institute	2008	50
20234191	12367	Tanjoni I	PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.	Cancer biology and therapy	2010	46
21471572	12367	Gaiser S	Intracellular activation of trypsinogen in transgenic mice induces acute but not chronic pancreatitis.	Gut	2011	36
21725296	12367	Huang Q	Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy.	Nature medicine	2011	150
23621987	12367	Meier-Abt F	Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium.	Breast cancer research 	2013	35
24642486	12367	Lao Y	The natural compound oblongifolin C inhibits autophagic flux and enhances antitumor efficacy of nutrient deprivation.	Autophagy	2014	20
25692960	12367	Hou Z	UV-emitting upconversion-based TiO2 photosensitizing nanoplatform: near-infrared light mediated in vivo photodynamic therapy via mitochondria-involved apoptosis pathway.	ACS nano	2015	17
25787076	12367	Silva KA	Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.	The Journal of biological chemistry	2015	20
25866249	12367	Liu X	Caspase-3 promotes genetic instability and carcinogenesis.	Molecular cell	2015	26
27668795	12367	Zanganeh S	Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues.	Nature nanotechnology	2016	19
7526156	12387	Reynolds AB	Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes.	Molecular and cellular biology	1994	122
9671767	12387	de La Coste A	Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.	Proceedings of the National Academy of Sciences of the United States of America	1998	212
9734399	12387	Lefebvre AM	Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice.	Nature medicine	1998	138
9845363	12387	Gat U	De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin.	Cell	1998	297
10362259	12387	Crawford HC	The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors.	Oncogene	1999	136
10545105	12387	Harada N	Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene.	The EMBO journal	1999	418
11834740	12387	van Noort M	Wnt signaling controls the phosphorylation status of beta-catenin.	The Journal of biological chemistry	2002	171
11983872	12387	Cheon SS	beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds.	Proceedings of the National Academy of Sciences of the United States of America	2002	86
12426568	12387	Kielman MF	Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling.	Nature genetics	2002	91
12626757	12387	Maretto S	Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors.	Proceedings of the National Academy of Sciences of the United States of America	2003	327
12702582	12387	Howe LR	Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation.	Cancer research	2003	78
12954714	12387	Braun KM	Manipulation of stem cell proliferation and lineage commitment: visualisation of label-retaining cells in wholemounts of mouse epidermis.	Development	2003	128
14611673	12387	Tanaka T	A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate.	Cancer science	2003	169
14668413	12387	Merrill BJ	Tcf3: a transcriptional regulator of axis induction in the early embryo.	Development	2004	93
15024077	12387	Müller-Tidow C	Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.	Molecular and cellular biology	2004	70
15084463	12387	Lo Celso C	Transient activation of beta-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours.	Development	2004	108
15131783	12387	Ireland H	Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin.	Gastroenterology	2004	103
15132997	12387	Akiyama H	Interactions between Sox9 and beta-catenin control chondrocyte differentiation.	Genes and development	2004	211
15306667	12387	Jamieson CH	Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.	The New England journal of medicine	2004	387
15314234	12387	Emami KH	A small molecule inhibitor of beta-catenin/CREB-binding protein transcription corrected.	Proceedings of the National Academy of Sciences of the United States of America	2004	196
15992546	12387	Silva-Vargas V	Beta-catenin and Hedgehog signal strength can specify number and location of hair follicles in adult epidermis without recruitment of bulge stem cells.	Developmental cell	2005	78
16007074	12387	Nateri AS	Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development.	Nature	2005	109
16885339	12387	Proweller A	Impaired notch signaling promotes de novo squamous cell carcinoma formation.	Cancer research	2006	69
17227796	12387	Chen MS	Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line.	Journal of cell science	2007	67
17785439	12387	Fevr T	Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells.	Molecular and cellular biology	2007	131
17893240	12387	Caldwell CM	APC mutations lead to cytokinetic failures in vitro and tetraploid genotypes in Min mice.	The Journal of cell biology	2007	55
17897439	12387	Schlange T	Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.	Breast cancer research 	2007	73
17929301	12387	Apte U	Wnt/beta-catenin signaling mediates oval cell response in rodents.	Hepatology	2008	56
18006687	12387	Delmas V	Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development.	Genes and development	2007	84
18068630	12387	Zhao C	Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.	Cancer cell	2007	184
18077429	12387	Gounaris E	Mast cells are an essential hematopoietic component for polyp development.	Proceedings of the National Academy of Sciences of the United States of America	2007	82
18094333	12387	Edwards CM	Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.	Blood	2008	62
18242220	12387	Siveke JT	Notch signaling is required for exocrine regeneration after acute pancreatitis.	Gastroenterology	2008	59
18393386	12387	Tan X	Beta-catenin deletion in hepatoblasts disrupts hepatic morphogenesis and survival during mouse development.	Hepatology	2008	60
18725219	12387	Heiser PW	Stabilization of beta-catenin induces pancreas tumor formation.	Gastroenterology	2008	55
18765787	12387	Grigoryan T	Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice.	Genes and development	2008	209
18768809	12387	Fujishita T	Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.	Proceedings of the National Academy of Sciences of the United States of America	2008	55
18806829	12387	Jeong JW	beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus.	Oncogene	2009	54
18818703	12387	Hu Y	beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.	Leukemia	2009	60
19047173	12387	Wang G	Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.	Cancer research	2008	52
19092805	12387	Zhu L	Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation.	Nature	2009	196
19154719	12387	Phng LK	Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis.	Developmental cell	2009	93
19165927	12387	Yang SH	Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling.	Nature genetics	2008	56
19718050	12387	van Zijl F	Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge.	Oncogene	2009	51
19841737	12387	Davis R	Nicotine promotes tumor growth and metastasis in mouse models of lung cancer.	PloS one	2009	48
19850960	12387	Fox JG	Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens.	Gut	2010	49
20010698	12387	Maes C	Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones.	The EMBO journal	2010	43
20071774	12387	Morris JP 4th	Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice.	The Journal of clinical investigation	2010	119
20106872	12387	Berthon A	Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development.	Human molecular genetics	2010	51
20133717	12387	Zhang M	Selective targeting of radiation-resistant tumor-initiating cells.	Proceedings of the National Academy of Sciences of the United States of America	2010	65
20339075	12387	Wang Y	The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.	Science	2010	206
20388854	12387	Li Y	Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells.	Clinical cancer research 	2010	112
20432254	12387	Nejak-Bowen KN	Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin.	Hepatology	2010	52
20580720	12387	Lee G	Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis.	Gastroenterology	2010	56
21858114	12387	Sinnberg T	β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance.	PloS one	2011	36
22665063	12387	Gallagher SJ	Beta-catenin inhibits melanocyte migration but induces melanoma metastasis.	Oncogene	2013	28
22722829	12387	Robinson G	Novel mutations target distinct subgroups of medulloblastoma.	Nature	2012	215
22800756	12387	Heaton JH	Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin.	The American journal of pathology	2012	36
22811581	12387	Lachenmayer A	Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.	Clinical cancer research 	2012	52
25964079	12387	Yuan SX	Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1.	Hepatology	2016	36
26908355	12387	Sarris ME	Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.	Cancer cell	2016	12
8565077	12394	Okuda T	AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.	Cell	1996	414
11526243	12394	Yuan Y	AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.	Proceedings of the National Academy of Sciences of the United States of America	2001	92
11533236	12394	Amann JM	ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.	Molecular and cellular biology	2001	92
12086889	12394	Higuchi M	Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.	Cancer cell	2002	106
16446141	12394	Chen CL	Runx1 determines nociceptive sensory neuron phenotype and is required for thermal and neuropathic pain.	Neuron	2006	94
16892037	12394	Yan M	A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.	Nature medicine	2006	88
18037406	12394	Ito Y	RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes.	Advances in cancer research	2008	73
18832181	12394	Li Z	Distinct microRNA expression profiles in acute myeloid leukemia with common translocations.	Proceedings of the National Academy of Sciences of the United States of America	2008	144
19182774	12394	Lancrin C	The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage.	Nature	2009	166
19339691	12394	Zuber J	Mouse models of human AML accurately predict chemotherapy response.	Genes and development	2009	74
22325351	12394	Yu M	Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors.	Molecular cell	2012	54
23325226	12394	Lou S	Runx1 controls terminal morphology and mechanosensitivity of VGLUT3-expressing C-mechanoreceptors.	The Journal of neuroscience 	2013	39
23979164	12394	Goyama S	Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.	The Journal of clinical investigation	2013	35
24326267	12394	Swiers G	Early dynamic fate changes in haemogenic endothelium characterized at the single-cell level.	Nature communications	2013	34
25802202	12394	Browne G	Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion.	Journal of cellular physiology	2015	15
27670082	12394	Matsuo J	Identification of Stem Cells in the Epithelium of the Stomach Corpus and Antrum of Mice.	Gastroenterology	2017	9
7557388	12443	Fantl V	Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.	Genes and development	1995	173
7664341	12443	Sicinski P	Cyclin D1 provides a link between development and oncogenesis in the retina and breast.	Cell	1995	248
8208295	12443	Wang TC	Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.	Nature	1994	211
9679152	12443	St Croix B	E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1).	The Journal of cell biology	1998	103
10611246	12443	Lee RJ	Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.	Molecular and cellular biology	2000	93
11074003	12443	Kenney AM	Sonic hedgehog promotes G(1) cyclin expression and sustained cell cycle progression in mammalian neuronal precursors.	Molecular and cellular biology	2000	149
11124803	12443	Alt JR	Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation.	Genes and development	2000	151
11402335	12443	Shaulian E	AP-1 in cell proliferation and survival.	Oncogene	2001	320
11429595	12443	Yu Q	Specific protection against breast cancers by cyclin D1 ablation.	Nature	2001	259
12502747	12443	Ciemerych MA	Development of mice expressing a single D-type cyclin.	Genes and development	2002	84
12777630	12443	Oliver TG	Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors.	Proceedings of the National Academy of Sciences of the United States of America	2003	98
14551132	12443	Chen BJ	Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease.	Blood	2004	72
15315760	12443	Kozar K	Mouse development and cell proliferation in the absence of D-cyclins.	Cell	2004	195
15355971	12443	Williams TM	Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion.	The Journal of biological chemistry	2004	84
15713663	12443	Fu M	Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment.	The Journal of biological chemistry	2005	72
16413468	12443	Landis MW	Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis.	Cancer cell	2006	96
17341655	12443	Blanco-Aparicio C	PTEN, more than the AKT pathway.	Carcinogenesis	2007	113
17890319	12443	Cao Y	IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	65
18239128	12443	Peer D	Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target.	Science	2008	99
18537191	12443	Zhang Y	Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation.	Hepatology	2008	54
18803638	12443	Tomimoto A	Metformin suppresses intestinal polyp growth in ApcMin/+ mice.	Cancer science	2008	54
18981289	12443	Maran RR	Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.	The Journal of pharmacology and experimental therapeutics	2009	57
19735646	12443	Anand P	Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo.	Biochemical pharmacology	2010	85
19874425	12443	Rattan R	Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.	Journal of cellular and molecular medicine	2011	56
20090754	12443	Bienvenu F	Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen.	Nature	2010	85
20129248	12443	Jeselsohn R	Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis.	Cancer cell	2010	62
20133621	12443	Beleut M	Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland.	Proceedings of the National Academy of Sciences of the United States of America	2010	102
20406885	12443	Bitler BG	MUC1 regulates nuclear localization and function of the epidermal growth factor receptor.	Journal of cell science	2010	46
21532889	12443	Rattan R	Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.	Neoplasia	2011	76
22307325	12443	Casimiro MC	ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice.	The Journal of clinical investigation	2012	39
22326957	12443	Ng R	A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration.	The Journal of clinical investigation	2012	47
22949014	12443	Wickström M	Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.	International journal of cancer	2013	26
23079655	12443	Choi YJ	The requirement for cyclin D function in tumor maintenance.	Cancer cell	2012	63
23187803	12443	Leontieva OV	Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.	Cell cycle	2012	62
23543735	12443	Chen L	Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression.	The Journal of biological chemistry	2013	28
24870244	12443	Lee Y	Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression.	Nature	2014	23
24954587	12443	Degirolamo C	Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.	Hepatology	2015	16
10430624	12477	van Elsas A	Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.	The Journal of experimental medicine	1999	254
10811122	12477	Hurwitz AA	Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.	Cancer research	2000	97
11390438	12477	Taylor PA	CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade.	The Journal of experimental medicine	2001	109
12682289	12477	Hodi FS	Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.	Proceedings of the National Academy of Sciences of the United States of America	2003	185
15599732	12477	Blank C	Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.	Cancer immunology, immunotherapy 	2005	88
15701862	12477	Demaria S	Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.	Clinical cancer research 	2005	173
16186187	12477	Ko K	Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.	The Journal of experimental medicine	2005	112
16710025	12477	Beck KE	Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.	Journal of clinical oncology 	2006	116
17404100	12477	Fecci PE	Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.	Clinical cancer research 	2007	78
18725522	12477	Quezada SA	Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.	The Journal of experimental medicine	2008	83
18845758	12477	Wing K	CTLA-4 control over Foxp3+ regulatory T cell function.	Science	2008	618
18941113	12477	Houot R	T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.	Blood	2009	52
19581407	12477	Peggs KS	Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.	The Journal of experimental medicine	2009	213
19706802	12477	Dewan MZ	Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.	Clinical cancer research 	2009	177
19738077	12477	Curran MA	Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.	Cancer research	2009	45
20156971	12477	Quezada SA	Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.	The Journal of experimental medicine	2010	187
20445343	12477	Mangsbo SM	Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.	Journal of immunotherapy	2010	43
21074057	12477	Weber J	Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.	Seminars in oncology	2010	69
21559358	12477	Curran MA	Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.	PloS one	2011	67
22108823	12477	Waitz R	Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.	Cancer research	2012	38
22576343	12477	Agarwalla P	Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.	Journal of immunotherapy	2012	32
22753941	12477	Corse E	Cutting edge: CTLA-4 on effector T cells inhibits in trans.	Journal of immunology	2012	34
22945631	12477	Ruocco MG	Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.	The Journal of clinical investigation	2012	52
23511566	12477	Quezada SA	Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.	British journal of cancer	2013	26
23633484	12477	Duraiswamy J	Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.	Cancer research	2013	128
23728179	12477	Marabelle A	Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.	The Journal of clinical investigation	2013	72
23983257	12477	Allard B	Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.	Clinical cancer research 	2013	42
24078774	12477	Akbay EA	Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.	Cancer discovery	2013	151
24277150	12477	Vom Berg J	Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection.	The Journal of experimental medicine	2013	38
24687957	12477	Fan X	Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.	The Journal of experimental medicine	2014	29
24691018	12477	Wainwright DA	Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.	Clinical cancer research 	2014	79
24732076	12477	Bulliard Y	OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.	Immunology and cell biology	2014	36
24777248	12477	Selby MJ	Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.	Cancer immunology research	2013	105
24778278	12477	Redmond WL	Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.	Cancer immunology research	2014	21
24829760	12477	Spranger S	Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.	Journal for immunotherapy of cancer	2014	68
24856586	12477	Özdemir BC	Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.	Cancer cell	2014	242
24892807	12477	Herrmann A	CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.	The Journal of clinical investigation	2014	24
25013914	12477	Belcaid Z	Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.	PloS one	2014	32
25071169	12477	Kim K	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	52
25082815	12477	Zhu Y	CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.	Cancer research	2014	96
25363763	12477	Huang YH	CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.	Nature	2015	51
25428507	12477	Gubin MM	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.	Nature	2014	240
25582080	12477	Hannani D	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.	Cell research	2015	19
25754329	12477	Twyman-Saint Victor C	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.	Nature	2015	185
25970248	12477	Spranger S	Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.	Nature	2015	161
25992292	12477	Lussier DM	Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.	Journal for immunotherapy of cancer	2015	21
26187615	12477	Rojas JJ	Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.	Clinical cancer research 	2015	25
26321679	12477	Chang CH	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.	Cell	2015	131
26371185	12477	Paterson AM	Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.	The Journal of experimental medicine	2015	15
26541610	12477	Vétizou M	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.	Science	2015	108
26546453	12477	Reardon DA	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.	Cancer immunology research	2016	13
26607445	12477	Demaria O	STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.	Proceedings of the National Academy of Sciences of the United States of America	2015	16
26645196	12477	Peng W	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.	Cancer discovery	2016	46
27667683	12477	Gao J	Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.	Cell	2016	24
17600736	12478	Pao LI	B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity.	Immunity	2007	80
17855649	12478	Brentjens RJ	Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.	Clinical cancer research 	2007	113
18059271	12478	Depoil D	CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand.	Nature immunology	2008	98
19238016	12478	Hollyman D	Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.	Journal of immunotherapy	2009	50
19719389	12478	Tammana S	4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.	Human gene therapy	2010	43
20631379	12478	Kochenderfer JN	Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.	Blood	2010	71
21093320	12478	Belver L	MicroRNAs prevent the generation of autoreactive antibodies.	Immunity	2010	50
21444674	12478	Olkhanud PB	Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells.	Cancer research	2011	86
21558388	12478	Singh H	Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.	Cancer research	2011	51
22733078	12478	Kim D	CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.	Leukemia	2012	33
22797699	12478	Zhang Y	LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.	Blood	2012	36
23585892	12478	Davila ML	CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.	PloS one	2013	26
25582824	12478	Curran KJ	Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.	Molecular therapy 	2015	22
26374073	12478	Przepiorka D	FDA Approval: Blinatumomab.	Clinical cancer research 	2015	20
26759368	12478	Ma JS	Versatile strategy for controlling the specificity and activity of engineered T cells.	Proceedings of the National Academy of Sciences of the United States of America	2016	12
15172969	12482	Teeling JL	Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.	Blood	2004	104
16785532	12482	Teeling JL	The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.	Journal of immunology	2006	116
17880166	12482	Aina OH	From combinatorial chemistry to cancer-targeting peptides.	Molecular pharmaceutics	2007	61
18097037	12482	DiLillo DJ	Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.	Journal of immunology	2008	75
18172311	12482	Matsui W	Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.	Cancer research	2008	163
20194720	12482	DiLillo DJ	B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.	Journal of immunology	2010	56
20223920	12482	Beers SA	Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.	Blood	2010	59
22019587	12482	Horikawa M	Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.	The Journal of clinical investigation	2011	46
24326534	12482	Kohrt HE	Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.	Blood	2014	56
24358223	12482	Budde LE	Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.	PloS one	2013	35
25156126	12482	Engeland CE	CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.	Molecular therapy 	2014	52
16417656	12484	Sleeman KE	CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells.	Breast cancer research 	2006	112
16849684	12484	Asselin-Labat ML	Steroid hormone receptor status of mouse mammary stem cells.	Journal of the National Cancer Institute	2006	94
17062128	12484	Sheridan C	CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.	Breast cancer research 	2006	268
18025203	12484	Xu Y	Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking.	Journal of immunology	2007	97
18541018	12484	Grimshaw MJ	Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells.	Breast cancer research 	2008	92
19464919	12484	Tirino V	The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.	European journal of cardio-thoracic surgery 	2009	65
19906290	12484	Meyer MJ	Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines.	Breast cancer research 	2009	46
20804964	12484	Ishizawa K	Tumor-initiating cells are rare in many human tumors.	Cell stem cell	2010	73
21258409	12484	Hwang-Verslues WW	miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1.	Oncogene	2011	52
21719134	12484	Nanduri LS	Regeneration of irradiated salivary glands with stem cell marker expressing cells.	Radiotherapy and oncology 	2011	35
21996747	12484	Lo PK	CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.	Oncogene	2012	46
22698401	12484	Liu W	LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.	Cancer cell	2012	42
22992620	12484	Oliveras-Ferraros C	Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).	Cell cycle	2012	33
23845442	12484	Zheng Y	A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal.	Cancer cell	2013	33
23966295	12484	Balko JM	Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.	Cancer research	2013	28
25669750	12484	Goldman A	Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition.	Nature communications	2015	30
26735577	12484	Wang R	Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells.	Oncotarget	2016	17
7509044	12490	Lapidot T	A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.	Nature	1994	948
9616148	12490	Möhle R	The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1.	Blood	1998	109
11021753	12490	Jordan CT	The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.	Leukemia	2000	120
11796918	12490	Bunting KD	ABC transporters as phenotypic markers and functional regulators of stem cells.	Stem cells	2002	95
14568894	12490	Yeh ET	Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo.	Circulation	2003	83
16778814	12490	Cotsarelis G	Epithelial stem cells: a folliculocentric view.	The Journal of investigative dermatology	2006	121
17442778	12490	Wilson A	Dormant and self-renewing hematopoietic stem cells and their niches.	Annals of the New York Academy of Sciences	2007	60
19095944	12490	Colmone A	Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells.	Science	2008	150
19168635	12490	Lee K	Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	81
19570512	12490	Jin L	Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.	Cell stem cell	2009	104
21493893	12490	Jeong JO	Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy.	Circulation research	2011	50
24657442	12490	Lee M	Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo.	Biochemical and biophysical research communications	2014	24
24894716	12490	De Francesco EM	GPER mediates activation of HIF1α/VEGF signaling by estrogens.	Cancer research	2014	22
24957147	12490	Gallipoli P	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.	Blood	2014	22
1910207	12504	Grusby MJ	Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice.	Science	1991	205
3262426	12504	Veillette A	The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck.	Cell	1988	364
7678351	12504	Townsend SE	Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.	Science	1993	145
8104230	12504	Brunda MJ	Antitumor and antimetastatic activity of interleukin 12 against murine tumors.	The Journal of experimental medicine	1993	163
9448305	12504	Staveley-O'Carroll K	Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.	Proceedings of the National Academy of Sciences of the United States of America	1998	145
10395322	12504	Diehl L	CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.	Nature medicine	1999	97
10395323	12504	Sotomayor EM	Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.	Nature medicine	1999	101
10397255	12504	Onizuka S	Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.	Cancer research	1999	214
10553041	12504	Shimizu J	Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.	Journal of immunology	1999	281
11313376	12504	Gabrilovich DI	Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.	Journal of immunology	2001	127
11742993	12504	Reichardt HM	Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor.	The EMBO journal	2001	89
11937556	12504	Belkaid Y	CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.	Journal of immunology	2002	84
12042807	12504	Teshima T	Acute graft-versus-host disease does not require alloantigen expression on host epithelium.	Nature medicine	2002	114
12871639	12504	Serbina NV	TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection.	Immunity	2003	343
12907617	12504	Kusmartsev S	All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.	Cancer research	2003	121
12907622	12504	Nowak AK	Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.	Cancer research	2003	89
12925844	12504	Edinger M	CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.	Nature medicine	2003	304
15036232	12504	Baecher-Allan C	Human CD4+CD25+ regulatory T cells.	Seminars in immunology	2004	91
15064759	12504	Yang Y	Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance.	Nature immunology	2004	110
15292057	12504	Taylor PA	L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection.	Blood	2004	102
15381730	12504	Turk MJ	Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.	The Journal of experimental medicine	2004	164
15728465	12504	Antony PA	CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.	Journal of immunology	2005	233
15753211	12504	Yu P	Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.	The Journal of experimental medicine	2005	100
15766662	12504	Drake CG	Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.	Cancer cell	2005	86
15833879	12504	Guiducci C	Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.	Cancer research	2005	122
15883172	12504	Ercolini AM	Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.	The Journal of experimental medicine	2005	137
15899788	12504	Erdman SE	CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice.	Cancer research	2005	69
16227988	12504	Zhang H	Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.	Nature medicine	2005	109
16275765	12504	Crowe NY	Differential antitumor immunity mediated by NKT cell subsets in vivo.	The Journal of experimental medicine	2005	115
16304057	12504	Ahmadzadeh M	IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.	Blood	2006	163
16424187	12504	Smyth MJ	CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer.	Journal of immunology	2006	87
16651447	12504	Cohen AD	Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.	Cancer research	2006	66
16818744	12504	Jarnicki AG	Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.	Journal of immunology	2006	69
16861339	12504	Beyer M	Regulatory T cells in cancer.	Blood	2006	160
16921386	12504	Lu LF	Mast cells are essential intermediaries in regulatory T-cell tolerance.	Nature	2006	204
17079441	12504	Pellegatta S	Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.	Cancer research	2006	77
17164341	12504	Curti A	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells.	Blood	2007	81
17327412	12504	Perez-Diez A	CD4 cells can be more efficient at tumor rejection than CD8 cells.	Blood	2007	114
17613255	12504	Yamaguchi T	Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor.	Immunity	2007	77
17616639	12504	Litzinger MT	IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.	Blood	2007	64
18023370	12504	Van Laethem F	Deletion of CD4 and CD8 coreceptors permits generation of alphabetaT cells that recognize antigens independently of the MHC.	Immunity	2007	67
18544681	12504	Jiang Q	FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo.	Blood	2008	57
19143470	12504	Curtin JF	HMGB1 mediates endogenous TLR2 activation and brain tumor regression.	PLoS medicine	2009	117
19265127	12504	Blair PA	Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice.	Journal of immunology	2009	73
19500966	12504	Zhou X	Plasticity of CD4(+) FoxP3(+) T cells.	Current opinion in immunology	2009	114
19952961	12504	Wrzesinski C	Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.	Journal of immunotherapy	2010	81
20080755	12504	Yang PL	Immune effectors required for hepatitis B virus clearance.	Proceedings of the National Academy of Sciences of the United States of America	2010	55
20454651	12504	Cohen AD	Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.	PloS one	2010	65
20702612	12504	Kodumudi KN	A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.	Clinical cancer research 	2010	79
20844537	12504	Kim HJ	Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance.	Nature	2010	93
20890040	12504	Schreiber TH	Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.	The Journal of clinical investigation	2010	46
21035406	12504	Rakhra K	CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.	Cancer cell	2010	92
21045153	12504	Kreiter S	Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.	Cancer research	2010	43
21150709	12504	Fotin-Mleczek M	Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.	Journal of immunotherapy	2011	45
21304053	12504	Wilke CM	Th17 cells in cancer: help or hindrance?	Carcinogenesis	2011	52
21317389	12504	Michalek RD	Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets.	Journal of immunology	2011	272
21347344	12504	Satou Y	HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo.	PLoS pathogens	2011	72
21372217	12504	Hervas-Stubbs S	Direct effects of type I interferons on cells of the immune system.	Clinical cancer research 	2011	76
21383056	12504	Ma Y	Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.	The Journal of experimental medicine	2011	84
21593401	12504	Hippen KL	Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.	Science translational medicine	2011	103
22017441	12504	Weinberg AD	Science gone translational: the OX40 agonist story.	Immunological reviews	2011	44
22072556	12504	Srinivasan M	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.	Blood	2012	58
22080947	12504	Kang TW	Senescence surveillance of pre-malignant hepatocytes limits liver cancer development.	Nature	2011	189
22208977	12504	Schaue D	Maximizing tumor immunity with fractionated radiation.	International journal of radiation oncology, biology, physics	2012	64
22337996	12504	Van Lint S	Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy.	Cancer research	2012	31
23008334	12504	Hirschhorn-Cymerman D	Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.	The Journal of experimental medicine	2012	42
23079658	12504	Di Piazza M	Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting.	Cancer cell	2012	32
23193171	12504	Avraham T	Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema.	FASEB journal 	2013	30
23241878	12504	Cook KD	The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection.	Journal of immunology	2013	27
23418627	12504	Näslund TI	Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity.	Journal of immunology	2013	30
23636127	12504	Wei J	miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma.	Cancer research	2013	50
24114780	12504	Church SE	Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.	European journal of immunology	2014	24
24197130	12504	Alizadeh D	Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.	Cancer research	2014	56
24303979	12504	Seddiki N	Role of miR-155 in the regulation of lymphocyte immune function and disease.	Immunology	2014	40
24416730	12504	Schaer DA	GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.	Cancer immunology research	2013	30
24586709	12504	Guo Z	PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.	PloS one	2014	29
24607504	12504	Keenan BP	A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.	Gastroenterology	2014	22
24679471	12504	Gold MJ	Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures.	The Journal of allergy and clinical immunology	2014	29
24780756	12504	Ding ZC	Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.	Cancer research	2014	22
24812273	12504	Fu J	Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.	Cancer research	2014	29
25223704	12504	Yin Y	Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth.	Cell research	2014	23
25412660	12504	Sheng W	STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation.	Cell research	2014	29
25716473	12504	Shiao SL	TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy.	Cancer immunology research	2015	24
25869387	12504	Filatenkov A	Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.	Clinical cancer research 	2015	22
25888329	12504	Beatty GL	Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.	Gastroenterology	2015	27
25893604	12504	Pollizzi KN	mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation.	The Journal of clinical investigation	2015	40
25901682	12504	Kreiter S	Mutant MHC class II epitopes drive therapeutic immune responses to cancer.	Nature	2015	80
25924064	12504	Gagliani N	Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation.	Nature	2015	90
26321681	12504	Ho PC	Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.	Cell	2015	96
26472910	12504	Kim HJ	Stable inhibitory activity of regulatory T cells requires the transcription factor Helios.	Science	2015	37
26660519	12504	Niemann CU	Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.	Clinical cancer research 	2016	13
26903244	12504	Yue X	Control of Foxp3 stability through modulation of TET activity.	The Journal of experimental medicine	2016	18
27317260	12504	Wang Y	Histone Deacetylase SIRT1 Negatively Regulates the Differentiation of Interleukin-9-Producing CD4(+) T Cells.	Immunity	2016	11
9887098	12505	Yu Q	Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion.	Genes and development	1999	141
10027409	12505	Wielenga VJ	Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway.	The American journal of pathology	1999	137
16550188	12505	Hasegawa H	Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I.	Nature medicine	2006	95
17548814	12505	Dalerba P	Phenotypic characterization of human colorectal cancer stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	571
18467123	12505	Naor D	Involvement of CD44, a molecule with a thousand faces, in cancer dissemination.	Seminars in cancer biology	2008	75
19072981	12505	Chu P	Characterization of a subpopulation of colon cancer cells with stem cell-like properties.	International journal of cancer	2009	49
19244169	12505	Vlashi E	In vivo imaging, tracking, and targeting of cancer stem cells.	Journal of the National Cancer Institute	2009	80
19415765	12505	Takaishi S	Identification of gastric cancer stem cells using the cell surface marker CD44.	Stem cells	2009	215
19965872	12505	Takahashi E	Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction.	The Journal of biological chemistry	2010	54
20197461	12505	Xu Y	CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.	Cancer research	2010	54
21240262	12505	Liu C	The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.	Nature medicine	2011	359
21393860	12505	Brown RL	CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression.	The Journal of clinical investigation	2011	133
21622730	12505	Pramanik D	Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice.	Molecular cancer therapeutics	2011	94
21864475	12505	Li C	c-Met is a marker of pancreatic cancer stem cells and therapeutic target.	Gastroenterology	2011	109
22359577	12505	Dubrovska A	CXCR4 expression in prostate cancer progenitor cells.	PloS one	2012	34
23589310	12505	Khurana SS	The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation.	The Journal of biological chemistry	2013	29
23633482	12505	Hiraga T	Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production.	Cancer research	2013	66
23760401	12505	Bjorklund CC	Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.	Leukemia	2014	23
24096479	12505	Bessède E	Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes.	Oncogene	2014	33
24162813	12505	Krause DS	Differential regulation of myeloid leukemias by the bone marrow microenvironment.	Nature medicine	2013	56
24395741	12505	Kinugasa Y	CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment.	Stem cells	2014	23
25053293	12505	Fernando J	A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.	International journal of cancer	2015	17
25181692	12505	Wan S	Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.	Gastroenterology	2014	54
25574084	12505	Zhao Y	Stem cells in gastric cancer.	World journal of gastroenterology	2015	16
25797261	12505	Gao Y	Knockdown of CD44 inhibits the invasion and metastasis of hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-mesenchymal transition.	Oncotarget	2015	15
25999946	12505	Misra S	Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer.	Frontiers in immunology	2015	33
2070412	12550	Vleminckx K	Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.	Cell	1991	315
9269988	12550	Foster BA	Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.	Cancer research	1997	129
9515965	12550	Perl AK	A causal role for E-cadherin in the transition from adenoma to carcinoma.	Nature	1998	344
10655586	12550	Cano A	The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.	Nature cell biology	2000	907
12508111	12550	Bolós V	The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors.	Journal of cell science	2003	289
15548370	12550	Xie L	Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro.	Neoplasia	2004	126
16489022	12550	Deckers M	The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.	Cancer research	2006	96
17097565	12550	Derksen PW	Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.	Cancer cell	2006	160
17611683	12550	Kajiyama H	Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.	International journal of oncology	2007	116
18156212	12550	Chiaverotti T	Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.	The American journal of pathology	2008	74
18192284	12550	Liu Y	Zeb1 links epithelial-mesenchymal transition and cellular senescence.	Development	2008	86
18411277	12550	Korpal M	The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2.	The Journal of biological chemistry	2008	517
19188353	12550	Rhee KJ	Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice.	Infection and immunity	2009	61
19362090	12550	von Burstin J	E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.	Gastroenterology	2009	100
19414595	12550	Smit MA	A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis.	Molecular and cellular biology	2009	58
19759263	12550	Olson P	MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.	Genes and development	2009	91
19816418	12550	Bao S	Epigenetic reversion of post-implantation epiblast to pluripotent embryonic stem cells.	Nature	2009	130
19909744	12550	Zhang B	Antimetastatic role of Smad4 signaling in colorectal cancer.	Gastroenterology	2010	51
20452298	12550	Weigelt B	Histological types of breast cancer: how special are they?	Molecular oncology	2010	56
20886123	12550	Tilghman RW	Matrix rigidity regulates cancer cell growth and cellular phenotype.	PloS one	2010	63
20959362	12550	Huang PH	Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases.	Molecular pharmacology	2011	35
21060868	12550	Lewis-Tuffin LJ	Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype.	PloS one	2010	47
21102519	12550	Roy LD	MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition.	Oncogene	2011	80
21159608	12550	Reka AK	Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition.	Molecular cancer therapeutics	2010	44
21330634	12550	Powolny AA	Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer.	Journal of the National Cancer Institute	2011	43
21490395	12550	Pacheco-Pinedo EC	Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium.	The Journal of clinical investigation	2011	52
21613543	12550	Wendt MK	Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer.	Molecular biology of the cell	2011	40
21822286	12550	Korpal M	Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.	Nature medicine	2011	191
22273460	12550	Bonde AK	Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors.	BMC cancer	2012	44
23013135	12550	Yokobori T	MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1.	Cancer science	2013	33
23381389	12550	Cong N	Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/β-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma.	Oncology reports	2013	27
24590176	12550	Shamir ER	Twist1-induced dissemination preserves epithelial identity and requires E-cadherin.	The Journal of cell biology	2014	38
25230372	12550	Sun Y	MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.	The Journal of pathology	2015	32
25970250	12550	Fernández-Sánchez ME	Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure.	Nature	2015	26
27375020	12550	Zhang Q	Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition.	Oncogene	2017	9
27439973	12550	Fan Y	Decreased expression of the long noncoding RNA LINC00261 indicate poor prognosis in gastric cancer and suppress gastric cancer metastasis by affecting the epithelial-mesenchymal transition.	Journal of hematology and oncology	2016	12
6287003	12575	Furth ME	Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.	Journal of virology	1982	229
7664346	12575	Deng C	Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.	Cell	1995	457
8012956	12575	Michieli P	Induction of WAF1/CIP1 by a p53-independent pathway.	Cancer research	1994	125
9271434	12575	Sewing A	High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1.	Molecular and cellular biology	1997	105
9448003	12575	Lanni JS	Characterization of the p53-dependent postmitotic checkpoint following spindle disruption.	Molecular and cellular biology	1998	135
9707425	12575	Venkatachalam S	Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.	The EMBO journal	1998	100
10710306	12575	Cheng T	Hematopoietic stem cell quiescence maintained by p21cip1/waf1.	Science	2000	399
11507077	12575	Martín-Caballero J	Tumor susceptibility of p21(Waf1/Cip1)-deficient mice.	Cancer research	2001	88
12479224	12575	Gartel AL	The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.	Molecular cancer therapeutics	2002	224
16107691	12575	Ho JS	p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest.	Molecular and cellular biology	2005	86
16176927	12575	Rattan R	5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase.	The Journal of biological chemistry	2005	104
16407454	12575	Myzak MC	Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice.	FASEB journal 	2006	91
17143283	12575	Choudhury AR	Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation.	Nature genetics	2007	134
17588519	12575	Chen X	Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome.	Molecular cell	2007	100
18206965	12575	Lim ST	Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.	Molecular cell	2008	146
19033664	12575	Hui L	Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation.	The Journal of clinical investigation	2008	81
19122635	12575	Viale A	Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells.	Nature	2009	92
20028735	12575	Zupkovitz G	The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation.	Molecular and cellular biology	2010	43
20110366	12575	Pewzner-Jung Y	A critical role for ceramide synthase 2 in liver homeostasis: II. insights into molecular changes leading to hepatopathy.	The Journal of biological chemistry	2010	52
20406979	12575	Wong P	The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression.	Cancer research	2010	61
21159648	12575	Siddiqui-Jain A	CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.	Cancer research	2010	82
21573166	12575	Kong G	Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model.	PloS one	2011	57
21816922	12575	Conkrite K	miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma.	Genes and development	2011	67
21900401	12575	Guan B	ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.	Cancer research	2011	91
22020437	12575	Choi YJ	miR-34 miRNAs provide a barrier for somatic cell reprogramming.	Nature cell biology	2011	133
23699408	12575	Inoue S	Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15.	Genes and development	2013	31
24994713	12575	Colvin TA	Hsp70-Bag3 interactions regulate cancer-related signaling networks.	Cancer research	2014	26
25564440	12575	Li X	Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer.	Molecular cancer therapeutics	2015	15
25613188	12575	Zheng L	Fumarate induces redox-dependent senescence by modifying glutathione metabolism.	Nature communications	2015	19
25663692	12575	Kim T	Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis.	Journal of the National Cancer Institute	2015	24
26192438	12575	Lu WY	Hepatic progenitor cells of biliary origin with liver repopulation capacity.	Nature cell biology	2015	49
26843616	12575	Benvenuto M	In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.	Oncotarget	2016	11
8629023	12576	Coats S	Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle.	Science	1996	143
8646779	12576	Nakayama K	Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.	Cell	1996	372
8646780	12576	Kiyokawa H	Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).	Cell	1996	323
8646781	12576	Fero ML	A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice.	Cell	1996	357
9823898	12576	Fero ML	The murine gene p27Kip1 is haplo-insufficient for tumour suppression.	Nature	1998	180
11175795	12576	Di Cristofano A	Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse.	Nature genetics	2001	139
11565035	12576	Malek NP	A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase.	Nature	2001	87
12507555	12576	Bloom J	Deregulated degradation of the cdk inhibitor p27 and malignant transformation.	Seminars in cancer biology	2003	78
14691534	12576	Trotman LC	Pten dose dictates cancer progression in the prostate.	PLoS biology	2003	228
16195383	12576	Karnik SK	Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c.	Proceedings of the National Academy of Sciences of the United States of America	2005	96
16391232	12576	Besson A	A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression.	Genes and development	2006	82
16495313	12576	Brooker R	Notch ligands with contrasting functions: Jagged1 and Delta1 in the mouse inner ear.	Development	2006	134
17626791	12576	Besson A	Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype.	Genes and development	2007	67
18274550	12576	Riccio O	Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2.	EMBO reports	2008	117
19858485	12576	Seluanov A	Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat.	Proceedings of the National Academy of Sciences of the United States of America	2009	69
19966802	12576	Wang H	Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.	Nature genetics	2010	51
23217425	12576	Li H	p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation.	Cell stem cell	2012	40
8620534	12578	Serrano M	Role of the INK4a locus in tumor suppression and cell mortality.	Cell	1996	376
9393858	12578	Kamijo T	Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.	Cell	1997	440
9653180	12578	Kamijo T	Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.	Proceedings of the National Academy of Sciences of the United States of America	1998	209
9851974	12578	Holland EC	A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice.	Genes and development	1998	140
10232611	12578	Kamijo T	Tumor spectrum in ARF-deficient mice.	Cancer research	1999	112
10911993	12578	Frank KM	DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway.	Molecular cell	2000	147
11212243	12578	Wetmore C	Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched.	Cancer research	2001	93
11485986	12578	Dai C	PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo.	Genes and development	2001	186
11544530	12578	Krimpenfort P	Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice.	Nature	2001	133
11751631	12578	Fisher GH	Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.	Genes and development	2001	185
12015983	12578	Schmitt CA	A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.	Cell	2002	247
12185367	12578	Lund AH	Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice.	Nature genetics	2002	83
12226664	12578	Bardeesy N	Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation.	Nature	2002	156
12359767	12578	Uhrbom L	Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.	Cancer research	2002	92
14681207	12578	Aguirre AJ	Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.	Genes and development	2003	325
14991053	12578	Bulavin DV	Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.	Nature genetics	2004	129
15489287	12578	Keller C	Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.	Genes and development	2004	105
15878778	12578	Sharpless NE	INK4a/ARF: a multifunctional tumor suppressor locus.	Mutation research	2005	113
15899789	12578	Ackermann J	Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.	Cancer research	2005	68
16585505	12578	Bardeesy N	Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.	Proceedings of the National Academy of Sciences of the United States of America	2006	191
16618932	12578	Williams RT	Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2006	83
16732270	12578	Montini E	Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.	Nature biotechnology	2006	224
16957737	12578	Krishnamurthy J	p16INK4a induces an age-dependent decline in islet regenerative potential.	Nature	2006	289
17114584	12578	Bardeesy N	Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.	Genes and development	2006	183
17450133	12578	Sarkisian CJ	Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis.	Nature cell biology	2007	149
17637672	12578	Matheu A	Delayed ageing through damage protection by the Arf/p53 pathway.	Nature	2007	166
17713536	12578	Krimpenfort P	p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a.	Nature	2007	84
18418377	12578	Akala OO	Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors.	Nature	2008	63
18483220	12578	Terzian T	The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.	Genes and development	2008	116
19013273	12578	Tomás-Loba A	Telomerase reverse transcriptase delays aging in cancer-resistant mice.	Cell	2008	93
19196966	12578	Zhu H	Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.	Proceedings of the National Academy of Sciences of the United States of America	2009	70
19217431	12578	Olson LE	Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis.	Developmental cell	2009	53
19246562	12578	Cullion K	Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.	Blood	2009	49
19435898	12578	Mukherjee B	EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.	Cancer research	2009	63
19668190	12578	Utikal J	Immortalization eliminates a roadblock during cellular reprogramming into iPS cells.	Nature	2009	309
20197468	12578	Becher OJ	Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma.	Cancer research	2010	53
20639864	12578	Johnson RA	Cross-species genomics matches driver mutations and cell compartments to model ependymoma.	Nature	2010	115
20708155	12578	Bennecke M	Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis.	Cancer cell	2010	50
20713517	12578	Inda MM	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.	Genes and development	2010	166
21458673	12578	Premsrirut PK	A rapid and scalable system for studying gene function in mice using conditional RNA interference.	Cell	2011	98
21665147	12578	Guerra C	Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence.	Cancer cell	2011	99
21730286	12578	Mei J	MicroRNA-146a inhibits glioma development by targeting Notch1.	Molecular and cellular biology	2011	44
21975932	12578	Jin X	EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction.	Cancer research	2011	41
22264792	12578	Ling J	KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.	Cancer cell	2012	125
22275380	12578	Zhang H	HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells.	Blood	2012	35
22872574	12578	Roberts PJ	Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.	Clinical cancer research 	2012	58
23103869	12578	Biankin AV	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.	Nature	2012	392
23332765	12578	Burd CE	Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model.	Cell	2013	53
23376950	12578	Braumüller H	T-helper-1-cell cytokines drive cancer into senescence.	Nature	2013	128
24622326	12578	Shao L	Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner.	Blood	2014	28
25395428	12578	Xu B	Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.	Blood	2015	38
26840489	12578	Baker DJ	Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan.	Nature	2016	122
15087398	12767	Tavor S	CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.	Cancer research	2004	72
15574767	12767	Smith MC	CXCR4 regulates growth of both primary and metastatic breast cancer.	Cancer research	2004	206
15647826	12767	Sun YX	Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.	Journal of bone and mineral research 	2005	101
18071913	12767	Kim SY	Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.	Clinical and experimental metastasis	2008	52
19050309	12767	Nervi B	Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.	Blood	2009	136
19332720	12767	Kamoun WS	Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.	Journal of clinical oncology 	2009	90
20179352	12767	Kioi M	Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.	The Journal of clinical investigation	2010	185
20237412	12767	Jablonska J	Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model.	The Journal of clinical investigation	2010	81
21618540	12767	Ping YF	The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.	The Journal of pathology	2011	48
21742774	12767	Righi E	CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.	Cancer research	2011	43
22294553	12767	Eberl M	Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells.	EMBO molecular medicine	2012	50
22815651	12767	Campbell JP	Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice.	PLoS biology	2012	45
22952424	12767	Domanska UM	CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.	Neoplasia	2012	36
23213054	12767	Kuhne MR	BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.	Clinical cancer research 	2013	49
23509246	12767	Gil M	Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases.	Proceedings of the National Academy of Sciences of the United States of America	2013	37
23813475	12767	Bertran E	Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells.	Hepatology	2013	27
24242874	12767	Chen Y	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.	Hepatology	2014	26
25529917	12767	Chen Y	CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.	Hepatology	2015	29
25662009	12767	McDermott DH	Chromothriptic cure of WHIM syndrome.	Cell	2015	20
25736399	12767	Philipp-Abbrederis K	In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.	EMBO molecular medicine	2015	19
26058075	12767	Pitt LA	CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance.	Cancer cell	2015	29
26761620	12767	Liu Y	Human Induced Pluripotent Stem Cells for Tumor Targeted Delivery of Gold Nanorods and Enhanced Photothermal Therapy.	ACS nano	2016	11
16462739	12772	Serbina NV	Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2.	Nature immunology	2006	444
17257744	12772	Huang B	CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.	Cancer letters	2007	87
18089798	12772	Klopp AH	Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment.	Cancer research	2007	78
18303997	12772	Serbina NV	Monocyte-mediated defense against microbial pathogens.	Annual review of immunology	2008	337
18375791	12772	Sawanobori Y	Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.	Blood	2008	99
18453605	12772	Jia T	Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocytogenes infection.	Journal of immunology	2008	83
19720836	12772	Lu X	Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone.	The Journal of biological chemistry	2009	64
19773434	12772	Popivanova BK	Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice.	Cancer research	2009	60
21131425	12772	Lim JK	Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis.	Journal of immunology	2011	59
21248750	12772	Zaidi MR	Interferon-γ links ultraviolet radiation to melanomagenesis in mice.	Nature	2011	66
21610146	12772	Moon EK	Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.	Clinical cancer research 	2011	65
21654748	12772	Qian BZ	CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.	Nature	2011	432
22516258	12772	Nakasone ES	Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.	Cancer cell	2012	101
22719068	12772	Movahedi K	Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages.	Cancer research	2012	39
22789541	12772	Wolf MJ	Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway.	Cancer cell	2012	49
23081697	12772	Zhao L	Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis.	Hepatology	2013	38
23168163	12772	Ren G	CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα.	Cell stem cell	2012	57
23243025	12772	Belarbi K	CCR2 deficiency prevents neuronal dysfunction and cognitive impairments induced by cranial irradiation.	Cancer research	2013	26
23653148	12772	Sanford DE	Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.	Clinical cancer research 	2013	81
23686489	12772	Lança T	Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.	Journal of immunology	2013	37
23928703	12772	Lin TH	Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.	Cell death and disease	2013	34
24302580	12772	Ma Y	CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.	Cancer research	2014	25
24695541	12772	Morganti JM	Cranial irradiation alters the brain's microenvironment and permits CCR2+ macrophage infiltration.	PloS one	2014	21
25337873	12772	Bonapace L	Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.	Nature	2014	70
26452628	12772	Li X	Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.	Gut	2017	24
27354473	12772	Kalbasi A	Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma.	Clinical cancer research 	2017	6
27444755	12772	Sager HB	Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure.	Circulation research	2016	18
9389480	12822	Boehm T	Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.	Nature	1997	187
11257139	12977	Lin EY	Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.	The Journal of experimental medicine	2001	424
16337366	12977	Chitu V	Colony-stimulating factor-1 in immunity and inflammation.	Current opinion in immunology	2006	148
19109434	12977	Wang S	Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
19398755	12977	Kubota Y	M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis.	The Journal of experimental medicine	2009	95
20018620	12977	Ojalvo LS	Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors.	Journal of immunology	2010	59
21822305	12977	Pyonteck SM	Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development.	Oncogene	2012	30
22039576	12977	DeNardo DG	Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.	Cancer discovery	2011	353
22294205	12977	Coniglio SJ	Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling.	Molecular medicine	2012	58
23372702	12977	Ryder M	Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.	PloS one	2013	28
25573988	12977	Caescu CI	Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.	Blood	2015	17
8097319	12981	Dranoff G	Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.	Proceedings of the National Academy of Sciences of the United States of America	1993	428
8202532	12981	Stanley E	Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.	Proceedings of the National Academy of Sciences of the United States of America	1994	158
12119235	12981	Seymour JF	Pulmonary alveolar proteinosis: progress in the first 44 years.	American journal of respiratory and critical care medicine	2002	95
12595888	12981	Liu BL	ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.	Gene therapy	2003	114
16474424	12981	Shi Y	Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know.	Cell research	2006	80
17557120	12981	Jinushi M	MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF.	The Journal of clinical investigation	2007	63
18192401	12981	Ohnishi N	Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.	Proceedings of the National Academy of Sciences of the United States of America	2008	163
19208793	12981	Li B	Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.	Clinical cancer research 	2009	56
19223554	12981	Eubank TD	Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages.	Cancer research	2009	50
19346489	12981	Shojaei F	G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.	Proceedings of the National Academy of Sciences of the United States of America	2009	112
19898981	12981	Morales JK	GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.	Breast cancer research and treatment	2010	52
19941314	12981	Dolcetti L	Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.	European journal of immunology	2010	143
19956757	12981	Liao D	Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model.	PloS one	2009	100
21954284	12981	Youn JI	Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.	Journal of leukocyte biology	2012	88
21969559	12981	Meyer C	Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.	Proceedings of the National Academy of Sciences of the United States of America	2011	69
22698406	12981	Bayne LJ	Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.	Cancer cell	2012	178
22698407	12981	Pylayeva-Gupta Y	Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.	Cancer cell	2012	143
23796475	12981	Kapanadze T	Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.	Journal of hepatology	2013	29
23817426	12981	Husain Z	Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells.	Journal of immunology	2013	39
24091328	12981	Waight JD	Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.	The Journal of clinical investigation	2013	51
24480625	12981	Ali OA	Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.	Cancer research	2014	21
25388222	12981	Huen SC	GM-CSF Promotes Macrophage Alternative Activation after Renal Ischemia/Reperfusion Injury.	Journal of the American Society of Nephrology 	2015	15
25877890	12981	Fu J	STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.	Science translational medicine	2015	44
26084029	12981	Helft J	GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells.	Immunity	2015	61
7521686	12985	Lieschke GJ	Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization.	Blood	1994	163
17145859	12985	Bumm TG	Characterization of murine JAK2V617F-positive myeloproliferative disease.	Cancer research	2006	60
18573909	12985	Kroenke MA	IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.	The Journal of experimental medicine	2008	184
19062086	12985	Wilson A	Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair.	Cell	2008	452
22826226	12985	Demers M	Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis.	Proceedings of the National Academy of Sciences of the United States of America	2012	100
25034888	12985	Chow A	Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB.	Scientific reports	2014	35
25624500	12985	Casbon AJ	Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
25822788	12985	Coffelt SB	IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.	Nature	2015	98
11756544	13433	Liang G	Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements.	Molecular and cellular biology	2002	130
12702876	13433	Gaudet F	Induction of tumors in mice by genomic hypomethylation.	Science	2003	341
16204030	13433	Karpf AR	Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells.	Cancer research	2005	74
16565708	13433	Gonzalo S	DNA methyltransferases control telomere length and telomere recombination in mammalian cells.	Nature cell biology	2006	154
17621273	13433	Howard G	Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice.	Oncogene	2008	89
22323818	13433	Song J	Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation.	Science	2012	59
23416117	13433	Zhang C	Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation.	Biochemical pharmacology	2013	32
25908435	13433	Pathania R	DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis.	Nature communications	2015	22
8653789	13555	Yamasaki L	Tumor induction and tissue atrophy in mice lacking E2F-1.	Cell	1996	177
9774968	13555	Tsai KY	Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos.	Molecular cell	1998	108
11719808	13555	Wu L	The E2F1-3 transcription factors are essential for cellular proliferation.	Nature	2001	184
16766265	13555	Fedele M	HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.	Cancer cell	2006	73
20016602	13555	Chong JL	E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells.	Nature	2009	92
22341444	13555	Raimundo N	Mitochondrial stress engages E2F1 apoptotic signaling to cause deafness.	Cell	2012	52
8052651	13649	Nishikawa R	A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.	Proceedings of the National Academy of Sciences of the United States of America	1994	231
9990038	13649	Tice DA	Mechanism of biological synergy between cellular Src and epidermal growth factor receptor.	Proceedings of the National Academy of Sciences of the United States of America	1999	129
11684709	13649	Mariotti A	EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion.	The Journal of cell biology	2001	87
11818567	13649	Roberts RB	Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2002	82
12695504	13649	Schenk S	Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution.	The Journal of cell biology	2003	77
12791272	13649	Zenz R	c-Jun regulates eyelid closure and skin tumor development through EGFR signaling.	Developmental cell	2003	89
14603439	13649	Pandita A	Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR.	Genes, chromosomes and cancer	2004	88
15289342	13649	Huang S	Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.	Cancer research	2004	74
16187797	13649	Greulich H	Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.	PLoS medicine	2005	186
16609043	13649	Sarkaria JN	Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.	Clinical cancer research 	2006	100
16648858	13649	Ferby I	Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.	Nature medicine	2006	84
16672372	13649	Ji H	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2006	73
16705038	13649	Politi K	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.	Genes and development	2006	128
16912195	13649	Carey KD	Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.	Cancer research	2006	93
17262214	13649	Cai W	Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody.	European journal of nuclear medicine and molecular imaging	2007	63
17548515	13649	Curto M	Contact-dependent inhibition of EGFR signaling by Nf2/Merlin.	The Journal of cell biology	2007	116
17613438	13649	Li D	Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.	Cancer cell	2007	76
17940036	13649	Natarajan A	The EGF receptor is required for efficient liver regeneration.	Proceedings of the National Academy of Sciences of the United States of America	2007	73
17999740	13649	Sibilia M	The epidermal growth factor receptor: from development to tumorigenesis.	Differentiation; research in biological diversity	2007	85
18454306	13649	Stern DF	ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.	Journal of mammary gland biology and neoplasia	2008	59
18632637	13649	Shimamura T	Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.	Cancer research	2008	57
18664652	13649	Gril B	Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.	Journal of the National Cancer Institute	2008	76
18800267	13649	Burgess AW	EGFR family: structure physiology signalling and therapeutic targets.	Growth factors	2008	69
19190345	13649	Schnidar H	Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway.	Cancer research	2009	71
19234449	13649	Keng VW	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma.	Nature biotechnology	2009	81
19249398	13649	Shi G	Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia.	Gastroenterology	2009	63
19452131	13649	Li T	Skin toxicities associated with epidermal growth factor receptor inhibitors.	Targeted oncology	2009	50
19567914	13649	Schoeberl B	Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.	Science signaling	2009	109
19572747	13649	Mallidi S	Multiwavelength photoacoustic imaging and plasmon resonance coupling of gold nanoparticles for selective detection of cancer.	Nano letters	2009	87
19581946	13649	Li PC	In vivo photoacoustic molecular imaging with simultaneous multiple selective targeting using antibody-conjugated gold nanorods.	Optics express	2008	64
19684613	13649	Li C	Nuclear EGFR contributes to acquired resistance to cetuximab.	Oncogene	2009	90
19734934	13649	Namiki Y	A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery.	Nature nanotechnology	2009	46
19759520	13649	Regales L	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.	The Journal of clinical investigation	2009	112
20009104	13649	Guo D	EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.	Science signaling	2009	72
20033049	13649	Zhou W	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.	Nature	2009	221
20067773	13649	Zhang X	A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.	Biochemical pharmacology	2010	49
20141840	13649	Lichtenberger BM	Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development.	Cell	2010	87
20159552	13649	Long W	SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration.	Molecular cell	2010	52
20215504	13649	Schoeberl B	An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.	Cancer research	2010	91
20471303	13649	Lai SY	Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.	Drug resistance updates 	2010	44
20978205	13649	Chou YT	EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.	Cancer research	2010	74
21216930	13649	Song L	JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.	Molecular cancer therapeutics	2011	37
21436589	13649	Cascone T	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.	The Journal of clinical investigation	2011	41
21508310	13649	Thakor AS	The fate and toxicity of Raman-active silica-gold nanoparticles in mice.	Science translational medicine	2011	38
21653642	13649	Zhu H	EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators.	Molecular cancer research 	2011	41
21907921	13649	Taguchi A	Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.	Cancer cell	2011	63
22011930	13649	Taskar KS	Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.	Pharmaceutical research	2012	38
22131831	13649	Reuveni T	Targeted gold nanoparticles enable molecular CT imaging of cancer: an in vivo study.	International journal of nanomedicine	2011	45
22203241	13649	Tichauer KM	In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging.	Molecular imaging and biology 	2012	38
22552292	13649	Xu L	Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.	Cancer research	2012	37
22990672	13649	Yang X	Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.	Molecular therapy 	2013	32
23032975	13649	Ohno S	Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells.	Molecular therapy 	2013	146
23169551	13649	Yang J	Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway.	Stem cells	2013	49
23248284	13649	Choi BD	Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
23481268	13649	Kwon MC	Mouse models for lung cancer.	Molecular oncology	2013	27
23532334	13649	Bean GR	PUMA and BIM are required for oncogene inactivation-induced apoptosis.	Science signaling	2013	31
23966300	13649	Lichtenberger BM	Epidermal EGFR controls cutaneous host defense and prevents inflammation.	Science translational medicine	2013	28
24331411	13649	Li B	MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.	Lung cancer	2014	32
24726384	13649	Xie H	Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells.	Cell metabolism	2014	71
24837434	13649	Kohrt HE	Targeting CD137 enhances the efficacy of cetuximab.	The Journal of clinical investigation	2014	42
25173978	13649	Lanaya H	EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.	Nature cell biology	2014	24
25596178	13649	Martinelli P	The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.	Gut	2016	12
25696001	13649	Johnson LA	Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.	Science translational medicine	2015	54
25925741	13649	Dong S	The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.	Journal of hematology and oncology	2015	21
25948633	13649	Ercan D	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.	Clinical cancer research 	2015	32
25981042	13649	Oshiumi H	DDX60 Is Involved in RIG-I-Dependent and Independent Antiviral Responses, and Its Function Is Attenuated by Virus-Induced EGFR Activation.	Cell reports	2015	16
26330166	13649	Liu X	Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.	Cancer research	2015	36
26387848	13649	Shu D	Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.	ACS nano	2015	19
26595119	13649	Antaris AL	A small-molecule dye for NIR-II imaging.	Nature materials	2016	21
27050072	13649	Chen X	A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.	Oncotarget	2016	10
27251290	13649	Jia Y	Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.	Nature	2016	22
27402485	13649	Zhang Y	Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.	Gut	2017	7
9155017	13684	Waskiewicz AJ	Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.	The EMBO journal	1997	219
15601771	13684	Kentsis A	Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap.	Proceedings of the National Academy of Sciences of the United States of America	2004	77
17786246	13684	Graff JR	Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.	The Journal of clinical investigation	2007	114
18055695	13684	Wendel HG	Dissecting eIF4E action in tumorigenesis.	Genes and development	2007	141
18551192	13684	Bordeleau ME	Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model.	The Journal of clinical investigation	2008	82
20679199	13684	Furic L	eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2010	102
22508483	13684	Martineau Y	Anti-oncogenic potential of the eIF4E-binding proteins.	Oncogene	2013	28
22552098	13684	Thoreen CC	A unifying model for mTORC1-mediated regulation of mRNA translation.	Nature	2012	330
24909168	13684	Robichaud N	Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3.	Oncogene	2015	26
25466251	13684	Gkogkas CG	Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.	Cell reports	2014	23
26095252	13684	Truitt ML	Differential Requirements for eIF4E Dose in Normal Development and Cancer.	Cell	2015	33
10562296	13805	Bourdeau A	A murine model of hereditary hemorrhagic telangiectasia.	The Journal of clinical investigation	1999	110
11121063	13805	Chang YS	Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood.	Proceedings of the National Academy of Sciences of the United States of America	2000	121
12773481	13805	Duff SE	CD105 is important for angiogenesis: evidence and potential applications.	FASEB journal 	2003	101
17200371	13805	Korpanty G	Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.	Clinical cancer research 	2007	73
17596885	13805	Banas A	Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes.	Hepatology	2007	95
17804725	13805	Liao MJ	Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity.	Cancer research	2007	64
18381930	13805	Dallas NA	Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.	Clinical cancer research 	2008	91
18614581	13805	Bussolati B	Identification of a tumor-initiating stem cell population in human renal carcinomas.	FASEB journal 	2008	74
21339349	13805	Deshpande N	Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging.	Radiology	2011	47
21373764	13805	Hong H	Positron emission tomography imaging of CD105 expression during tumor angiogenesis.	European journal of nuclear medicine and molecular imaging	2011	52
21670082	13805	Grange C	Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche.	Cancer research	2011	176
22174762	13805	Zhang Y	Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA.	PloS one	2011	35
22386918	13805	Hong H	In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene.	Biomaterials	2012	33
23374706	13805	Shi S	Tumor vasculature targeting and imaging in living mice with reduced graphene oxide.	Biomaterials	2013	35
23401487	13805	Anderberg C	Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination.	The Journal of experimental medicine	2013	29
24083623	13805	Chen F	In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles.	ACS nano	2013	46
12011461	13819	Jögi A	Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype.	Proceedings of the National Academy of Sciences of the United States of America	2002	100
16054088	13819	Mansfield KD	Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation.	Cell metabolism	2005	184
17097563	13819	Holmquist-Mengelbier L	Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype.	Cancer cell	2006	181
17284606	13819	Gruber M	Acute postnatal ablation of Hif-2alpha results in anemia.	Proceedings of the National Academy of Sciences of the United States of America	2007	143
17404621	13819	Rankin EB	Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo.	The Journal of clinical investigation	2007	159
17418410	13819	Gordan JD	HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity.	Cancer cell	2007	247
18347341	13819	Ginouvès A	PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis.	Proceedings of the National Academy of Sciences of the United States of America	2008	64
18490920	13819	Rankin EB	Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice.	Oncogene	2008	52
19439736	13819	Skuli N	Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis.	Blood	2009	75
19662677	13819	Kim WY	HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.	The Journal of clinical investigation	2009	46
19805192	13819	Lee K	Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization.	Proceedings of the National Academy of Sciences of the United States of America	2009	105
20197624	13819	Hickey MM	The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice.	The Journal of clinical investigation	2010	51
20644254	13819	Imtiyaz HZ	Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation.	The Journal of clinical investigation	2010	91
20660313	13819	Mazumdar J	HIF-2alpha deletion promotes Kras-driven lung tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
22426208	13819	Skuli N	Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes.	The Journal of clinical investigation	2012	54
24095676	13819	Rouault-Pierre K	HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress.	Cell stem cell	2013	30
27595393	13819	Cho H	On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.	Nature	2016	16
1359541	13866	Guy CT	Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.	Proceedings of the National Academy of Sciences of the United States of America	1992	321
2898299	13866	Muller WJ	Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.	Cell	1988	258
7477377	13866	Lee KF	Requirement for neuregulin receptor erbB2 in neural and cardiac development.	Nature	1995	249
9661897	13866	Baselga J	Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.	Cancer research	1998	122
10205169	13866	Siegel PM	Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.	The EMBO journal	1999	145
11325840	13866	Machiels JP	Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.	Cancer research	2001	123
11359907	13866	Laughner E	HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.	Molecular and cellular biology	2001	252
11984589	13866	Crone SA	ErbB2 is essential in the prevention of dilated cardiomyopathy.	Nature medicine	2002	161
12498714	13866	Moody SE	Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.	Cancer cell	2002	109
16125352	13866	Anisimov VN	Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.	Experimental gerontology	2005	116
16369543	13866	Bentires-Alj M	A role for the scaffolding adapter GAB2 in breast cancer.	Nature medicine	2006	67
16618759	13866	Orlova A	Tumor imaging using a picomolar affinity HER2 binding affibody molecule.	Cancer research	2006	90
16648555	13866	Bussey KJ	Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.	Molecular cancer therapeutics	2006	69
16901783	13866	Guo W	Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.	Cell	2006	170
16951186	13866	Campbell MJ	Breast cancer growth prevention by statins.	Cancer research	2006	72
17283148	13866	Tada H	In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice.	Cancer research	2007	84
17446858	13866	Ursini-Siegel J	Insights from transgenic mouse models of ERBB2-induced breast cancer.	Nature reviews. Cancer	2007	92
17606729	13866	Manning EA	A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.	Clinical cancer research 	2007	65
17711321	13866	Whiteaker JR	Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer.	Journal of proteome research	2007	75
17785729	13866	Sampath L	Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.	Journal of nuclear medicine 	2007	71
17875707	13866	Liu JC	Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.	Cancer research	2007	73
18008005	13866	Zuo T	FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.	The Journal of clinical investigation	2007	61
18167340	13866	Hüsemann Y	Systemic spread is an early step in breast cancer.	Cancer cell	2008	268
18559604	13866	Lee SB	Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging.	Clinical cancer research 	2008	58
18794144	13866	Lee YS	The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.	Cancer research	2008	70
19106626	13866	Vazquez-Martin A	The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.	Cell cycle	2009	72
19176373	13866	Ogawa M	In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green.	Cancer research	2009	69
19299620	13866	Bostrom J	Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.	Science	2009	95
19411449	13866	Sloan EK	Stromal cell expression of caveolin-1 predicts outcome in breast cancer.	The American journal of pathology	2009	82
19818098	13866	Coscia M	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.	Journal of cellular and molecular medicine	2010	64
19934303	13866	Miller TW	Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.	Clinical cancer research 	2009	50
20016287	13866	Anisimov VN	Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo.	Cell cycle	2010	56
20068073	13866	Ahmed N	HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.	Clinical cancer research 	2010	72
20124480	13866	Zahnd C	Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.	Cancer research	2010	51
20305377	13866	Martin-Castillo B	Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.	Cell cycle	2010	81
20363920	13866	Anisimov VN	Rapamycin extends maximal lifespan in cancer-prone mice.	The American journal of pathology	2010	104
20713705	13866	Huck L	beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression.	Proceedings of the National Academy of Sciences of the United States of America	2010	49
20813035	13866	Prat A	Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.	Breast cancer research 	2010	520
21081567	13866	Hainfeld JF	Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions.	The British journal of radiology	2011	36
21159656	13866	Liu M	The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion.	Cancer research	2010	52
21482773	13866	Stagg J	Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.	Proceedings of the National Academy of Sciences of the United States of America	2011	76
21499296	13866	Rexer BN	Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.	Oncogene	2011	47
21510863	13866	Barok M	Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.	Breast cancer research 	2011	41
21666715	13866	Kondratyev M	Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.	Oncogene	2012	46
21730275	13866	Morrow PK	Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.	Journal of clinical oncology 	2011	63
22267010	13866	Shen BQ	Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.	Nature biotechnology	2012	95
22397502	13866	Wang B	Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.	Breast cancer research 	2012	30
22819326	13866	Korkaya H	Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.	Molecular cell	2012	110
22908275	13866	Greulich H	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.	Proceedings of the National Academy of Sciences of the United States of America	2012	62
23543055	13866	Abel EV	Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.	The Journal of clinical investigation	2013	79
23569315	13866	Rimawi MF	Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.	Journal of clinical oncology 	2013	40
23873688	13866	John LB	Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.	Clinical cancer research 	2013	96
23940356	13866	Hanker AB	Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.	Proceedings of the National Academy of Sciences of the United States of America	2013	40
23943608	13866	Kirouac DC	Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.	Science signaling	2013	28
24097864	13866	Phillips GD	Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.	Clinical cancer research 	2014	28
24322659	13866	Zhu P	Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.	Cancer prevention research	2014	23
24556924	13866	Popovich IG	Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.	Cancer biology and therapy	2014	22
24845231	13866	Krishnan N	Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.	Nature chemical biology	2014	43
25196138	13866	Orecchioni S	The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.	International journal of cancer	2015	26
25277192	13866	Khan S	MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.	Oncotarget	2014	30
25416790	13866	Sato K	Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer.	Molecular cancer therapeutics	2015	16
25689852	13866	Hiroshima Y	Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern.	PloS one	2015	19
25739959	13866	Memmi EM	p63 Sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling.	Proceedings of the National Academy of Sciences of the United States of America	2015	38
25961456	13866	Abravanel DL	Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.	The Journal of clinical investigation	2015	16
26047477	13866	Hiroshima Y	Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models.	PloS one	2015	21
10976058	13982	Dupont S	Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes.	Development	2000	245
12588983	13982	Razandi M	Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane.	Molecular and cellular biology	2003	87
15231873	13982	Razandi M	Plasma membrane estrogen receptors exist and functions as dimers.	Molecular endocrinology	2004	86
16356836	13982	Garvin S	Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo.	Cancer letters	2006	63
16452162	13982	Mallepell S	Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland.	Proceedings of the National Academy of Sciences of the United States of America	2006	122
16645038	13982	Pedram A	Nature of functional estrogen receptors at the plasma membrane.	Molecular endocrinology	2006	150
16675129	13982	Cavalieri E	Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention.	Biochimica et biophysica acta	2006	117
16803960	13982	Musatov S	RNAi-mediated silencing of estrogen receptor {alpha} in the ventromedial nucleus of hypothalamus abolishes female sexual behaviors.	Proceedings of the National Academy of Sciences of the United States of America	2006	63
17046690	13982	Wintermantel TM	Definition of estrogen receptor pathway critical for estrogen positive feedback to gonadotropin-releasing hormone neurons and fertility.	Neuron	2006	180
17332335	13982	Gupta PB	Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers.	Cancer research	2007	56
17493263	13982	Herschkowitz JI	Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.	Genome biology	2007	413
17785410	13982	Feng Y	Estrogen receptor-alpha expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice.	Proceedings of the National Academy of Sciences of the United States of America	2007	71
17936613	13982	Morissette M	Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain.	The Journal of steroid biochemistry and molecular biology	2008	50
18055862	13982	Ricke WA	Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling.	FASEB journal 	2008	54
18256928	13982	Phoenix KN	Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.	Breast cancer research and treatment	2009	46
20179807	13982	Barh D	MicroRNA let-7: an emerging next-generation cancer therapeutic.	Current oncology	2010	73
20577047	13982	Chambliss KL	Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice.	The Journal of clinical investigation	2010	77
23379261	13982	Li Y	Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.	Molecular cancer	2013	35
25017071	13982	Nagarajan S	Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription.	Cell reports	2014	32
26599602	13982	Tam A	Sex Differences in Airway Remodeling in a Mouse Model of Chronic Obstructive Pulmonary Disease.	American journal of respiratory and critical care medicine	2016	11
20951942	14056	Wilson BG	Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.	Cancer cell	2010	123
21761357	14056	Doherty LF	In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer.	Hormones and cancer	2010	57
21941025	14056	Koh CM	Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.	Oncotarget	2011	55
22068036	14056	Wang C	EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.	Cancer research	2012	42
22233633	14056	Herrera-Merchan A	Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease.	Nature communications	2012	31
22431509	14056	Simon C	A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.	Genes and development	2012	71
22508723	14056	Hock H	A complex Polycomb issue: the two faces of EZH2 in cancer.	Genes and development	2012	38
22677129	14056	Tanaka S	Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.	Blood	2012	53
23051747	14056	McCabe MT	EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.	Nature	2012	386
23375371	14056	Pal B	Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2.	Cell reports	2013	29
23620515	14056	Knutson SK	Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.	Proceedings of the National Academy of Sciences of the United States of America	2013	112
23680150	14056	Béguelin W	EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.	Cancer cell	2013	120
23826629	14056	Leroy G	A quantitative atlas of histone modification signatures from human cancer cells.	Epigenetics and chromatin	2013	27
24055345	14056	Jung HY	PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation.	Molecular cell	2013	39
24563539	14056	Knutson SK	Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.	Molecular cancer therapeutics	2014	69
25477340	14056	Takeshima H	Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.	Carcinogenesis	2015	16
25600873	14056	de Vries NA	Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression.	Cell reports	2015	15
25609585	14056	Zingg D	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.	Nature communications	2015	37
26590165	14056	Hernando H	EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.	Molecular cancer therapeutics	2016	12
8707856	14083	Frisch SM	Control of adhesion-dependent cell survival by focal adhesion kinase.	The Journal of cell biology	1996	230
9694867	14083	Yu DH	Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion.	The Journal of biological chemistry	1998	102
11476890	14083	Schaller MD	Biochemical signals and biological responses elicited by the focal adhesion kinase.	Biochimica et biophysica acta	2001	129
12615911	14083	Hsia DA	Differential regulation of cell motility and invasion by FAK.	The Journal of cell biology	2003	135
15601818	14083	McLean GW	Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression.	Genes and development	2004	89
16069815	14083	McLean GW	The role of focal-adhesion kinase in cancer - a new therapeutic opportunity.	Nature reviews. Cancer	2005	261
17721515	14083	Serrels B	Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex.	Nature cell biology	2007	90
18006843	14083	Halder J	Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.	Cancer research	2007	69
18195107	14083	Lim Y	PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility.	The Journal of cell biology	2008	87
18339875	14083	Roberts WG	Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.	Cancer research	2008	120
18391070	14083	Weis SM	Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK.	The Journal of cell biology	2008	62
18845837	14083	Provenzano PP	Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.	The American journal of pathology	2008	65
19147559	14083	Luo M	Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.	Cancer research	2009	76
19147981	14083	Pylayeva Y	Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.	The Journal of clinical investigation	2009	104
19169797	14083	Zhao J	Signal transduction by focal adhesion kinase in cancer.	Cancer metastasis reviews	2009	171
19435801	14083	Tomar A	A FAK-p120RasGAP-p190RhoGAP complex regulates polarity in migrating cells.	Journal of cell science	2009	52
19502425	14083	Shibue T	Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs.	Proceedings of the National Academy of Sciences of the United States of America	2009	111
19643531	14083	Luo M	Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis.	Cancer letters	2010	55
19740433	14083	Wendt MK	Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.	Breast cancer research 	2009	58
20442405	14083	Lim ST	Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation.	The Journal of biological chemistry	2010	40
20538762	14083	Han HD	Targeted gene silencing using RGD-labeled chitosan nanoparticles.	Clinical cancer research 	2010	47
21118706	14083	Zhao X	Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis.	Advanced drug delivery reviews	2011	103
21119598	14083	Mitra AK	Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis.	Oncogene	2011	74
21665151	14083	Samuel MS	Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth.	Cancer cell	2011	126
21903606	14083	Stokes JB	Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.	Molecular cancer therapeutics	2011	52
21984450	14083	Lechertier T	Focal adhesion kinase and tumour angiogenesis.	The Journal of pathology	2012	33
22264731	14083	Chen XL	VEGF-induced vascular permeability is mediated by FAK.	Developmental cell	2012	83
24446483	14083	Jean C	Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function.	The Journal of cell biology	2014	26
24858039	14083	Havel LS	Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity.	Oncogene	2015	21
25079333	14083	Tavora B	Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy.	Nature	2014	20
26406376	14083	Serrels A	Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.	Cell	2015	31
27376576	14083	Jiang H	Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.	Nature medicine	2016	25
19092804	14160	Barker N	Crypt stem cells as the cells-of-origin of intestinal cancer.	Nature	2009	558
19136944	14160	Quigley DA	Genetic architecture of mouse skin inflammation and tumour susceptibility.	Nature	2009	66
20384634	14160	Uchida H	Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer.	Cancer science	2010	45
20417836	14160	Barker N	Leucine-rich repeat-containing G-protein-coupled receptors as markers of adult stem cells.	Gastroenterology	2010	95
21383077	14160	Gerbe F	Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epithelium.	The Journal of cell biology	2011	77
22264787	14160	Quante M	Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia.	Cancer cell	2012	88
22855427	14160	Schepers AG	Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas.	Science	2012	307
22895187	14160	Koo BK	Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors.	Nature	2012	119
23446353	14160	Buczacki SJ	Intestinal label-retaining cells are secretory precursors expressing Lgr5.	Nature	2013	164
23744940	14160	Sato T	Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications.	Science	2013	162
23752315	14160	Ju S	Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis.	Molecular therapy 	2013	31
24185900	14160	Hahn S	SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition.	The EMBO journal	2013	31
24282287	14160	Hirsch D	LGR5 positivity defines stem-like cells in colorectal cancer.	Carcinogenesis	2014	32
24292484	14160	Yin X	Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny.	Nature methods	2014	48
24355609	14160	Snippert HJ	Biased competition between Lgr5 intestinal stem cells driven by oncogenic mutation induces clonal expansion.	EMBO reports	2014	35
24531760	14160	Ritsma L	Intestinal crypt homeostasis revealed at single-stem-cell level by in vivo live imaging.	Nature	2014	96
24997521	14160	Ng A	Lgr5 marks stem/progenitor cells in ovary and tubal epithelia.	Nature cell biology	2014	24
25419707	14160	Davis H	Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche.	Nature medicine	2015	28
25725293	14160	Sigal M	Helicobacter pylori Activates and Expands Lgr5(+) Stem Cells Through Direct Colonization of the Gastric Glands.	Gastroenterology	2015	30
26266975	14160	Koren S	PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours.	Nature	2015	41
26503053	14160	Gregorieff A	Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer.	Nature	2015	31
9647657	14173	Seghezzi G	Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis.	The Journal of cell biology	1998	132
17909625	14173	Nissen LJ	Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.	The Journal of clinical investigation	2007	75
19351838	14173	Wakimoto H	Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.	Cancer research	2009	114
19541600	14173	Ezashi T	Derivation of induced pluripotent stem cells from pig somatic cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	109
21249423	14173	Tartour E	Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.	Cancer metastasis reviews	2011	70
21698156	14173	Zhou H	M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis.	PloS one	2011	41
22967508	14173	Cao R	Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis.	Proceedings of the National Academy of Sciences of the United States of America	2012	32
24013945	14173	Jetten N	Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo.	Angiogenesis	2014	55
25894825	14173	Ilkow CS	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.	Nature medicine	2015	21
11689883	14254	Lyden D	Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth.	Nature medicine	2001	383
15294883	14254	Ferrara N	Vascular endothelial growth factor: basic science and clinical progress.	Endocrine reviews	2004	610
15961063	14254	Ferrara N	Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.	Biochemical and biophysical research communications	2005	161
16226705	14254	Casanovas O	Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.	Cancer cell	2005	406
16341007	14254	Kaplan RN	VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.	Nature	2005	648
19538465	14254	Bergmann A	Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model.	Journal of cellular and molecular medicine	2010	41
20371352	14254	Bais C	PlGF blockade does not inhibit angiogenesis during primary tumor growth.	Cell	2010	50
21115742	14254	Roybal JD	miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.	Molecular cancer research 	2011	54
21623369	14254	Stefater JA 3rd	Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells.	Nature	2011	85
22228176	14254	De Falco S	The discovery of placenta growth factor and its biological activity.	Experimental and molecular medicine	2012	42
22866201	14254	Shibuya M	Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies.	Genes and cancer	2011	51
24332967	14254	Schoors S	Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis.	Cell metabolism	2014	53
25991856	14254	Yang X	VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2015	18
26861455	14254	Incio J	PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.	Clinical cancer research 	2016	14
10202929	14255	Fernandez NC	Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.	Nature medicine	1999	216
11090077	14255	Mizuki M	Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.	Blood	2000	103
11756186	14255	Kelly LM	FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.	Blood	2002	98
12010785	14255	Levis M	A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.	Blood	2002	86
12124173	14255	Weisberg E	Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.	Cancer cell	2002	89
12620411	14255	Armstrong SA	Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.	Cancer cell	2003	86
14726387	14255	Smith BD	Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.	Blood	2004	132
17541402	14255	Pardanani A	TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.	Leukemia	2007	69
18230792	14255	Zhang W	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.	Journal of the National Cancer Institute	2008	103
18485879	14255	Uren AG	Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks.	Cell	2008	92
22958930	14255	Chu SH	FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.	Cell stem cell	2012	38
24046014	14255	Zimmerman EI	Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.	Blood	2013	34
10725363	14632	Nilsson M	Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1.	Proceedings of the National Academy of Sciences of the United States of America	2000	96
15520185	14632	Hallahan AR	The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas.	Cancer research	2004	152
17392427	14632	Stecca B	Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways.	Proceedings of the National Academy of Sciences of the United States of America	2007	163
17628016	14632	Bar EE	Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma.	Stem cells	2007	188
17638910	14632	Dennler S	Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo.	Cancer research	2007	129
19136624	14632	Nolan-Stevaux O	GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation.	Genes and development	2009	148
19556240	14632	Das S	The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin.	The Journal of biological chemistry	2009	45
20107231	14632	Merchant A	Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors.	Blood	2010	45
20395211	14632	Slusarz A	Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer.	Cancer research	2010	53
20581804	14632	Po A	Hedgehog controls neural stem cells through p53-independent regulation of Nanog.	The EMBO journal	2010	71
23129257	14632	Li SH	Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway.	Molecular and cellular biochemistry	2013	28
23482563	14632	Mills LD	Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation.	The Journal of biological chemistry	2013	31
15856015	15234	Cheng N	Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.	Oncogene	2005	97
15922853	15234	Christensen JG	c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.	Cancer letters	2005	112
16452232	15234	Burgess T	Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.	Cancer research	2006	65
16565519	15234	Yoo MH	Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells.	The Journal of biological chemistry	2006	65
19098908	15234	Stein U	MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis.	Nature medicine	2009	105
19470725	15234	Knowles LM	HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.	Clinical cancer research 	2009	51
19920187	15234	Jedeszko C	Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ.	Cancer research	2009	45
21199531	15234	Nakamura T	Hepatocyte growth factor twenty years on: Much more than a growth factor.	Journal of gastroenterology and hepatology	2011	80
22095660	15234	Ishikawa T	Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice.	Hepatology	2012	39
23818496	15234	Graveel CR	MET: a critical player in tumorigenesis and therapeutic target.	Cold Spring Harbor perspectives in biology	2013	29
24284055	15234	Cañadas I	Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.	Clinical cancer research 	2014	28
25985180	15234	Finisguerra V	MET is required for the recruitment of anti-tumoural neutrophils.	Nature	2015	27
10861440	15251	Zagzag D	Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression.	Cancer	2000	111
12671019	15251	Yeo EJ	YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.	Journal of the National Cancer Institute	2003	84
12761491	15251	Unruh A	The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy.	Oncogene	2003	79
12957288	15251	Blouw B	The hypoxic response of tumors is dependent on their microenvironment.	Cancer cell	2003	110
16809770	15251	Laderoute KR	5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments.	Molecular and cellular biology	2006	167
17234764	15251	Liao D	Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression.	Cancer research	2007	115
18974394	15251	Greenberger LM	A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.	Molecular cancer therapeutics	2008	51
19057015	15251	Botusan IR	Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice.	Proceedings of the National Academy of Sciences of the United States of America	2008	75
19065050	15251	Cantley J	Deletion of the von Hippel-Lindau gene in pancreatic beta cells impairs glucose homeostasis in mice.	The Journal of clinical investigation	2009	50
19276158	15251	Xie H	LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.	Molecular cancer therapeutics	2009	82
19541609	15251	Shackelford DB	mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2009	67
19584228	15251	Rapisarda A	Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.	Molecular cancer therapeutics	2009	51
20141841	15251	Zhong L	The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha.	Cell	2010	241
20609350	15251	Qi J	Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.	Cancer cell	2010	61
20620956	15251	Lim JH	Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha.	Molecular cell	2010	154
20841473	15251	Doedens AL	Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression.	Cancer research	2010	122
21358671	15251	Bell EL	SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production.	Oncogene	2011	112
21474104	15251	Wang Y	Targeting HIF1α eliminates cancer stem cells in hematological malignancies.	Cell stem cell	2011	97
21592963	15251	Liu Y	Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer.	The Journal of biological chemistry	2011	37
21871655	15251	Dang EV	Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1.	Cell	2011	297
21965273	15251	Wang H	Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α.	Carcinogenesis	2011	42
22225988	15251	Schwab LP	Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.	Breast cancer research 	2012	45
22484816	15251	Maione F	Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.	The Journal of clinical investigation	2012	32
22589271	15251	Haigis MC	SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis.	Cancer research	2012	44
22615958	15251	Kong J	Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA.	PloS one	2012	31
22719018	15251	Palazón A	The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.	Cancer discovery	2012	34
22925884	15251	Sasaki M	D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.	Genes and development	2012	69
23299930	15251	Liang Y	Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.	Hepatology	2013	46
23340180	15251	Zhang L	MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma.	Cancer letters	2013	27
23344526	15251	Storti P	Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.	Leukemia	2013	26
23906982	15251	Eisinger-Mathason TS	Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis.	Cancer discovery	2013	39
24336068	15251	Barsoum IB	A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.	Cancer research	2014	48
24778419	15251	Noman MZ	PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.	The Journal of experimental medicine	2014	133
24931163	15251	Dodd KM	mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3.	Oncogene	2015	18
25305448	15251	Xu W	Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway.	Cancer letters	2015	16
25385028	15251	Zhao T	LASP1 is a HIF1α target gene critical for metastasis of pancreatic cancer.	Cancer research	2015	17
25535359	15251	Amelio I	TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1α degradation.	Proceedings of the National Academy of Sciences of the United States of America	2015	20
26154152	15251	Won C	Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.	Hepatology	2015	16
26715642	15251	Lee KE	Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.	Cancer discovery	2016	12
27134166	15251	Allen E	Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.	Cell reports	2016	18
27374498	15251	Lampropoulou V	Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation.	Cell metabolism	2016	16
27798602	15251	Tyrakis PA	S-2-hydroxyglutarate regulates CD8&lt;sup&gt;+&lt;/sup&gt; T-lymphocyte fate.	Nature	2016	14
11740565	15270	Petersen S	AID is required to initiate Nbs1/gamma-H2AX focus formation and mutations at sites of class switching.	Nature	2001	175
12447390	15270	Fernandez-Capetillo O	DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1.	Nature cell biology	2002	194
12689589	15270	Fernandez-Capetillo O	H2AX is required for chromatin remodeling and inactivation of sex chromosomes in male mouse meiosis.	Developmental cell	2003	151
12897845	15270	Pilch DR	Characteristics of gamma-H2AX foci at DNA double-strand breaks sites.	Biochemistry and cell biology = Biochimie et biologie cellulaire	2003	129
12914700	15270	Bassing CH	Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors.	Cell	2003	167
14712078	15270	Bassing CH	H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity.	Cell cycle	2004	71
16030261	15270	McManus KJ	ATM-dependent DNA damage-independent mitotic phosphorylation of H2AX in normally growing mammalian cells.	Molecular biology of the cell	2005	73
19887611	15270	Trouiller B	Titanium dioxide nanoparticles induce DNA damage and genetic instability in vivo in mice.	Cancer research	2009	49
25079315	15270	Flach J	Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells.	Nature	2014	92
26876348	15270	Ahuja AK	A short G1 phase imposes constitutive replication stress and fork remodelling in mouse embryonic stem cells.	Nature communications	2016	11
18083101	15364	Yu F	let-7 regulates self renewal and tumorigenicity of breast cancer cells.	Cell	2007	608
18308936	15364	Kumar MS	Suppression of non-small cell lung tumor development by the let-7 microRNA family.	Proceedings of the National Academy of Sciences of the United States of America	2008	283
23318420	15364	Guo L	Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition.	Oncogene	2013	49
23722545	15364	Morishita A	HMGA2 is a driver of tumor metastasis.	Cancer research	2013	56
23811688	15364	Copley MR	The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells.	Nature cell biology	2013	63
24305048	15364	Kumar MS	HMGA2 functions as a competing endogenous RNA to promote lung cancer progression.	Nature	2014	67
1643658	15461	Ridley AJ	The small GTP-binding protein rac regulates growth factor-induced membrane ruffling.	Cell	1992	907
3014349	15461	Quintanilla M	Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis.	Nature	1986	193
9334313	15461	Johnson L	K-ras is an essential gene in the mouse with partial functional overlap with N-ras.	Genes and development	1997	129
11156605	15461	Elenbaas B	Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells.	Genes and development	2001	313
11238881	15461	Esteban LM	Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development.	Molecular and cellular biology	2001	96
14996724	15461	Liu J	A genetically defined model for human ovarian cancer.	Cancer research	2004	96
20563706	15461	Castellano E	Role of RAS in the regulation of PI 3-kinase.	Current topics in microbiology and immunology	2010	40
21779497	15461	Castellano E	RAS Interaction with PI3K: More Than Just Another Effector Pathway.	Genes and cancer	2011	110
26168291	15461	Nassar D	Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma.	Nature medicine	2015	29
10537105	15901	Lyden D	Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts.	Nature	1999	227
11729207	15901	Korchynskyi O	Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter.	The Journal of biological chemistry	2002	237
18187653	15901	Gao D	Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis.	Science	2008	207
22264785	15901	Barrett LE	Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma.	Cancer cell	2012	58
22547771	15901	Flechsig P	LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals.	Clinical cancer research 	2012	37
14502282	15930	Uyttenhove C	Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.	Nature medicine	2003	382
15254595	15930	Munn DH	Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.	The Journal of clinical investigation	2004	206
15711557	15930	Muller AJ	Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.	Nature medicine	2005	205
17234791	15930	Hou DY	Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.	Cancer research	2007	138
18317452	15930	Prendergast GC	Immune escape as a fundamental trait of cancer: focus on IDO.	Oncogene	2008	70
18568076	15930	Reddy P	Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.	The Journal of clinical investigation	2008	95
18952840	15930	Muller AJ	Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.	Proceedings of the National Academy of Sciences of the United States of America	2008	75
19366986	15930	Sharma MD	Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.	Blood	2009	132
19635913	15930	Baban B	IDO activates regulatory T cells and blocks their conversion into Th17-like T cells.	Journal of immunology	2009	143
20124451	15930	Koblish HK	Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.	Molecular cancer therapeutics	2010	40
22822050	15930	Smith C	IDO is a nodal pathogenic driver of lung cancer and metastasis development.	Cancer discovery	2012	65
23264892	15930	Metz R	IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.	Oncoimmunology	2012	50
23752227	15930	Holmgaard RB	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.	The Journal of experimental medicine	2013	96
23986400	15930	Spranger S	Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.	Science translational medicine	2013	233
24402311	15930	Metz R	IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.	International immunology	2014	31
2163307	15978	Miyazaki J	Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms.	Endocrinology	1990	273
3933006	15978	Buchmeier NA	Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection.	Proceedings of the National Academy of Sciences of the United States of America	1985	173
9636188	15978	Kaplan DH	Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.	Proceedings of the National Academy of Sciences of the United States of America	1998	289
10694580	15978	Kim S	In vivo natural killer cell activities revealed by natural killer cell-deficient mice.	Proceedings of the National Academy of Sciences of the United States of America	2000	97
11009425	15978	Guttridge DC	NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia.	Science	2000	194
11133760	15978	Street SE	Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.	Blood	2001	106
11257133	15978	Smyth MJ	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.	The Journal of experimental medicine	2001	86
11323675	15978	Shankaran V	IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.	Nature	2001	495
11830474	15978	Smyth MJ	Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.	Blood	2002	104
11900991	15978	Colombo MP	Interleukin-12 in anti-tumor immunity and immunotherapy.	Cytokine and growth factor reviews	2002	137
12122110	15978	Dummer W	T cell homeostatic proliferation elicits effective antitumor autoimmunity.	The Journal of clinical investigation	2002	114
12154358	15978	Fujii S	Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.	Nature immunology	2002	140
12900519	15978	Gao Y	Gamma delta T cells provide an early source of interferon gamma in tumor immunity.	The Journal of experimental medicine	2003	76
14764678	15978	André F	Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.	Journal of immunology	2004	75
15286803	15978	Acharyya S	Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.	The Journal of clinical investigation	2004	133
15634881	15978	Sinha P	Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.	Journal of immunology	2005	152
15944250	15978	Lugade AA	Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.	Journal of immunology	2005	166
15951824	15978	Badovinac VP	Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination.	Nature medicine	2005	149
16444265	15978	Taieb J	A novel dendritic cell subset involved in tumor immunosurveillance.	Nature medicine	2006	96
16680149	15978	Uno T	Eradication of established tumors in mice by a combination antibody-based therapy.	Nature medicine	2006	62
17255288	15978	Bracci L	Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.	Clinical cancer research 	2007	62
18292536	15978	Lugade AA	Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.	Journal of immunology	2008	79
18317595	15978	Zhang B	IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.	The Journal of clinical investigation	2008	51
18972444	15978	Wang YD	Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.	Hepatology	2008	95
19130584	15978	Martin-Orozco N	Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells.	European journal of immunology	2009	115
19276342	15978	Ozao-Choy J	The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.	Cancer research	2009	151
19336265	15978	Le HK	Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.	International immunopharmacology	2009	88
19633655	15978	Liu J	Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice.	Nature medicine	2009	175
20388795	15978	Vincent J	5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.	Cancer research	2010	187
23135404	15978	Ouyang W	Novel Foxo1-dependent transcriptional programs control T(reg) cell function.	Nature	2012	84
23232398	15978	Kanhere A	T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements.	Nature communications	2012	46
25615236	15978	Gao W	Modulating antibacterial immunity via bacterial membrane-coated nanoparticles.	Nano letters	2015	21
10207053	16000	Frasca F	Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.	Molecular and cellular biology	1999	186
12610293	16000	Longo VD	Evolutionary medicine: from dwarf model systems to healthy centenarians?	Science	2003	154
18177265	16000	Kuro-o M	Klotho as a regulator of oxidative stress and senescence.	Biological chemistry	2008	56
18728386	16000	Anisimov VN	Metformin slows down aging and extends life span of female SHR mice.	Cell cycle	2008	77
19279572	16000	Kalaany NY	Tumours with PI3K activation are resistant to dietary restriction.	Nature	2009	120
19539012	16000	Stanfel MN	The TOR pathway comes of age.	Biochimica et biophysica acta	2009	128
20145127	16000	Lee C	Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index.	Cancer research	2010	59
20956999	16000	Clayton PE	Growth hormone, the insulin-like growth factor axis, insulin and cancer risk.	Nature reviews. Endocrinology	2011	57
21048967	16000	Penna F	Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition.	PloS one	2010	44
21084729	16000	Anisimov VN	Metformin for aging and cancer prevention.	Aging	2010	60
21245093	16000	Gao J	Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.	Cancer research	2011	38
21386129	16000	Anisimov VN	If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice.	Aging	2011	67
21949739	16000	White JP	The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse.	PloS one	2011	40
23434537	16000	Anisimov VN	The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer.	Critical reviews in oncology/hematology	2013	35
23591370	16000	Junnila RK	The GH/IGF-1 axis in ageing and longevity.	Nature reviews. Endocrinology	2013	61
23771523	16000	Quinn BJ	Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling.	Cancer prevention research	2013	26
24655348	16000	Leontieva OV	Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet.	Aging cell	2014	30
25619689	16000	Hofmann JW	Reduced expression of MYC increases longevity and enhances healthspan.	Cell	2015	30
26094889	16000	Brandhorst S	A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan.	Cell metabolism	2015	53
26172407	16000	Toth P	IGF-1 deficiency impairs neurovascular coupling in mice: implications for cerebromicrovascular aging.	Aging cell	2015	15
14729630	16001	Girnita A	Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.	Cancer research	2004	72
15756033	16001	Cohen BD	Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.	Clinical cancer research 	2005	86
18260118	16001	Kolb EA	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.	Pediatric blood and cancer	2008	59
19244128	16001	Dallas NA	Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.	Cancer research	2009	137
20085282	16001	Piersma SR	Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum.	Journal of proteome research	2010	41
20154720	16001	Eliasz S	Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway.	Oncogene	2010	61
20457905	16001	Ulanet DB	Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.	Proceedings of the National Academy of Sciences of the United States of America	2010	84
20924128	16001	Buck E	Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.	Molecular cancer therapeutics	2010	70
21429986	16001	Li P	IGF signaling directs ventricular cardiomyocyte proliferation during embryonic heart development.	Development	2011	43
21813472	16001	Kong KL	MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor.	Gut	2012	67
11016962	16168	Marks-Konczalik J	IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.	Proceedings of the National Academy of Sciences of the United States of America	2000	93
11208862	16168	Fehniger TA	Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells.	The Journal of experimental medicine	2001	95
12579196	16168	Brentjens RJ	Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.	Nature medicine	2003	160
14762166	16168	Klebanoff CA	IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.	Proceedings of the National Academy of Sciences of the United States of America	2004	167
15841203	16168	Melchionda F	Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.	The Journal of clinical investigation	2005	89
16474399	16168	Teague RM	Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.	Nature medicine	2006	67
17056533	16168	Stoklasek TA	Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.	Journal of immunology	2006	103
18413767	16168	Epardaud M	Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.	Cancer research	2008	56
18825750	16168	Hochweller K	A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells.	European journal of immunology	2008	52
19001550	16168	Quinn LS	Oversecretion of interleukin-15 from skeletal muscle reduces adiposity.	American journal of physiology. Endocrinology and metabolism	2009	48
20026737	16168	Inoue S	IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.	Journal of immunology	2010	64
20101095	16168	Zhu Q	Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.	The Journal of clinical investigation	2010	57
21233417	16168	Kim HJ	CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice.	Proceedings of the National Academy of Sciences of the United States of America	2011	47
21737507	16168	Klebanoff CA	Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.	Clinical cancer research 	2011	70
22496150	16168	Bergamaschi C	Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum.	Blood	2012	39
23153537	16168	Mishra A	Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation.	Cancer cell	2012	31
23209317	16168	Ni J	Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.	The Journal of experimental medicine	2012	69
25060519	16168	Nishio N	Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.	Cancer research	2014	29
25833053	16168	Seay K	In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice.	Journal of virology	2015	19
16478879	16452	Wernig G	Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.	Blood	2006	119
16670266	16452	Lacout C	JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.	Blood	2006	113
17183644	16452	Zaleskas VM	Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.	PloS one	2006	75
18033315	16452	Shide K	Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.	Leukemia	2008	52
18228120	16452	Wagner KU	Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression.	Journal of mammary gland biology and neoplasia	2008	56
18394554	16452	Wernig G	Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.	Cancer cell	2008	101
20197548	16452	Akada H	Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.	Blood	2010	77
20472827	16452	Marty C	Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.	Blood	2010	50
20489053	16452	Li J	JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.	Blood	2010	64
21691275	16452	Hart S	SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.	Leukemia	2011	36
22234689	16452	Walz C	Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.	Blood	2012	43
22286129	16452	Hantschel O	BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.	Nature chemical biology	2012	53
22820254	16452	Koppikar P	Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.	Nature	2012	60
8107827	16542	Millauer B	Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.	Nature	1994	162
10537299	16542	Prewett M	Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.	Cancer research	1999	131
11559524	16542	Kunkel P	Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.	Cancer research	2001	105
11577199	16542	Matsumoto K	Liver organogenesis promoted by endothelial cells prior to vascular function.	Science	2001	153
15520458	16542	Schiffelers RM	Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.	Nucleic acids research	2004	131
15577911	16542	Huber TL	Haemangioblast commitment is initiated in the primitive streak of the mouse embryo.	Nature	2004	177
15834403	16542	Fang J	Stable antibody expression at therapeutic levels using the 2A peptide.	Nature biotechnology	2005	115
16825198	16542	Gonzalez RR	Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2).	The Journal of biological chemistry	2006	66
17620431	16542	Kumar R	Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.	Molecular cancer therapeutics	2007	104
18180339	16542	Willmann JK	US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.	Radiology	2008	87
18443294	16542	Purhonen S	Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth.	Proceedings of the National Academy of Sciences of the United States of America	2008	121
18519694	16542	Dineen SP	Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice.	Cancer research	2008	64
18695212	16542	Willmann JK	Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice.	Radiology	2008	58
18772115	16542	Shaked Y	Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.	Cancer cell	2008	120
20027118	16542	Pochon S	BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.	Investigative radiology	2010	64
20515975	16542	Pysz MA	Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).	Radiology	2010	59
20631075	16542	Shrimali RK	Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.	Cancer research	2010	103
21098094	16542	Waldner MJ	VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer.	The Journal of experimental medicine	2010	46
21880786	16542	Stenzel D	Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis.	Development	2011	36
22689825	16542	Sun Z	VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd.	The Journal of experimental medicine	2012	39
22789536	16542	Lu KV	VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.	Cancer cell	2012	135
23045683	16542	Huang Y	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2012	112
23187125	16542	Pasula S	Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling.	The Journal of clinical investigation	2012	35
24401374	16542	Fantin A	Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis.	Development	2014	32
24416386	16542	Jardim-Perassi BV	Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer.	PloS one	2014	21
27383781	16542	Scialdone A	Resolving early mesoderm diversification through single-cell expression profiling.	Nature	2016	22
8465203	16653	Shirasawa S	Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.	Science	1993	177
11323676	16653	Johnson L	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.	Nature	2001	354
11751630	16653	Jackson EL	Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.	Genes and development	2001	557
12957286	16653	Guerra C	Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.	Cancer cell	2003	166
14706336	16653	Hingorani SR	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.	Cancer cell	2003	632
15093544	16653	Tuveson DA	Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.	Cancer cell	2004	278
15619626	16653	Dinulescu DM	Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.	Nature medicine	2005	163
15894267	16653	Hingorani SR	Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.	Cancer cell	2005	504
16288016	16653	Jackson EL	The differential effects of mutant p53 alleles on advanced murine lung cancer.	Cancer research	2005	176
16288213	16653	Ji H	K-ras activation generates an inflammatory response in lung tumors.	Oncogene	2006	84
16702406	16653	Lu SL	Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma.	Genes and development	2006	77
17030180	16653	Janssen KP	APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.	Gastroenterology	2006	86
17114585	16653	Ijichi H	Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.	Genes and development	2006	106
17217625	16653	Shih AH	Notch signaling enhances nestin expression in gliomas.	Neoplasia	2006	66
17349585	16653	Guerra C	Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.	Cancer cell	2007	297
17360542	16653	Carrière C	The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia.	Proceedings of the National Academy of Sciences of the United States of America	2007	63
17401365	16653	Kumar MS	Impaired microRNA processing enhances cellular transformation and tumorigenesis.	Nature genetics	2007	490
17591971	16653	Zhu L	Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia.	The American journal of pathology	2007	95
17676035	16653	Ji H	LKB1 modulates lung cancer differentiation and metastasis.	Nature	2007	306
17804720	16653	Kissil JL	Requirement for Rac1 in a K-ras induced lung cancer in the mouse.	Cancer research	2007	60
18344688	16653	Esquela-Kerscher A	The let-7 microRNA reduces tumor growth in mouse models of lung cancer.	Cell cycle	2008	192
18755941	16653	Podsypanina K	Seeding and propagation of untransformed mouse mammary cells in the lung.	Science	2008	110
19028870	16653	Habbe N	Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice.	Proceedings of the National Academy of Sciences of the United States of America	2008	118
19028876	16653	De La O JP	Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia.	Proceedings of the National Academy of Sciences of the United States of America	2008	131
19029981	16653	Engelman JA	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.	Nature medicine	2008	467
19147554	16653	Seeley ES	Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia.	Cancer research	2009	74
19292977	16653	Carrière C	Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras.	Biochemical and biophysical research communications	2009	65
19351816	16653	Miller KA	Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.	Cancer research	2009	45
19501586	16653	Ji B	Ras activity levels control the development of pancreatic diseases.	Gastroenterology	2009	71
19759262	16653	Gibbons DL	Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression.	Genes and development	2009	149
19789349	16653	Konstantinidou G	Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.	Cancer research	2009	54
19847165	16653	Meylan E	Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.	Nature	2009	179
20080688	16653	Hung KE	Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.	Proceedings of the National Academy of Sciences of the United States of America	2010	75
20081861	16653	Houghton AM	Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.	Nature medicine	2010	102
20129250	16653	Takahashi H	Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation.	Cancer cell	2010	124
20406971	16653	Bassères DS	Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis.	Cancer research	2010	58
20421486	16653	Weinberg F	Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity.	Proceedings of the National Academy of Sciences of the United States of America	2010	340
20484026	16653	Hanlon L	Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma.	Cancer research	2010	42
20495549	16653	Singh M	Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.	Nature biotechnology	2010	91
20541700	16653	Carretero J	Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.	Cancer cell	2010	100
20595231	16653	Zhao Z	p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.	Genes and development	2010	49
20675343	16653	Zhao WG	The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.	Carcinogenesis	2010	64
20807812	16653	Hill R	PTEN loss accelerates KrasG12D-induced pancreatic cancer development.	Cancer research	2010	56
20832755	16653	Hatley ME	Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21.	Cancer cell	2010	183
20972333	16653	Vicent S	Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.	The Journal of clinical investigation	2010	45
21107427	16653	Junttila MR	Selective activation of p53-mediated tumour suppression in high-grade tumours.	Nature	2010	80
21285251	16653	Sureban SM	DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism.	Cancer research	2011	64
21311774	16653	Ray KC	Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model.	PloS one	2011	36
21317887	16653	Schramek D	The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression.	Nature genetics	2011	35
21451123	16653	Lyubynska N	A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.	Science translational medicine	2011	39
21471965	16653	Winslow MM	Suppression of lung adenocarcinoma progression by Nkx2-1.	Nature	2011	119
21502497	16653	Lapouge G	Identifying the cellular origin of squamous skin tumors.	Proceedings of the National Academy of Sciences of the United States of America	2011	82
21555567	16653	Shaw AT	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress.	Proceedings of the National Academy of Sciences of the United States of America	2011	50
21586612	16653	Corcoran RB	STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.	Cancer research	2011	107
21710835	16653	Kamp DW	Chronic inflammation and cancer: the role of the mitochondria.	Oncology	2011	49
21847114	16653	Gaglio D	Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.	Molecular systems biology	2011	115
21874163	16653	Xue W	Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.	Cancer discovery	2011	35
21878506	16653	Deng M	miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma.	Journal of cell science	2011	37
21907929	16653	De Raedt T	Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.	Cancer cell	2011	72
21926469	16653	Ijichi H	Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.	The Journal of clinical investigation	2011	74
21984975	16653	Ying H	PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.	Cancer discovery	2011	56
22232209	16653	Collins MA	Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.	The Journal of clinical investigation	2012	141
22308361	16653	Cortez-Retamozo V	Origins of tumor-associated macrophages and neutrophils.	Proceedings of the National Academy of Sciences of the United States of America	2012	103
22406536	16653	Daniluk J	An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice.	The Journal of clinical investigation	2012	75
22411819	16653	Xu X	Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2012	57
22425996	16653	Chen Z	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.	Nature	2012	129
22430205	16653	Zhou C	The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis.	Oncogene	2013	32
22541435	16653	Ying H	Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.	Cell	2012	338
22565310	16653	Hamidi T	Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis.	The Journal of clinical investigation	2012	34
22654667	16653	Tran PT	Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.	PLoS genetics	2012	31
22825584	16653	Julien S	Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.	Clinical cancer research 	2012	64
22952217	16653	Gill BJ	A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model.	Cancer research	2012	30
22964582	16653	Kasinski AL	miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.	Cancer research	2012	65
23076356	16653	Chugh R	A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.	Science translational medicine	2012	47
23226501	16653	Collins MA	Metastatic pancreatic cancer is dependent on oncogenic Kras in mice.	PloS one	2012	35
23245996	16653	Corcoran RB	Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.	Cancer cell	2013	93
23352126	16653	Shackelford DB	LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.	Cancer cell	2013	133
23454899	16653	Molina-Arcas M	Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.	Cancer discovery	2013	30
23475959	16653	Soucek L	Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.	Genes and development	2013	68
23598351	16653	Flandez M	Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRas(G12V)-driven pancreatic tumourigenesis.	Gut	2014	25
23622131	16653	di Magliano MP	Roles for KRAS in pancreatic tumor development and progression.	Gastroenterology	2013	65
23715154	16653	Liu Y	Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.	Cancer discovery	2013	34
23824538	16653	Guo JY	Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis.	Genes and development	2013	121
23911236	16653	Patra KC	Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.	Cancer cell	2013	109
23958541	16653	Philip B	A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice.	Gastroenterology	2013	39
24045185	16653	Shimamura T	Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.	Clinical cancer research 	2013	49
24067278	16653	Neesse A	SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.	Gut	2014	39
24097820	16653	Zhang Y	Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.	Cancer research	2013	38
24163374	16653	Faber AC	mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.	Cancer discovery	2014	34
24444711	16653	Zhu Z	Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.	Cancer discovery	2014	36
24478710	16653	Collins MA	Kras as a key oncogene and therapeutic target in pancreatic cancer.	Frontiers in physiology	2013	38
24491301	16653	Moon BS	Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.	Journal of the National Cancer Institute	2014	25
24499815	16653	Desai TJ	Alveolar progenitor and stem cells in lung development, renewal and cancer.	Nature	2014	123
24586047	16653	Sutherland KD	Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	28
24675361	16653	Hata AN	Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.	Cancer research	2014	23
24875857	16653	Karsli-Uzunbas G	Autophagy is required for glucose homeostasis and lung tumor maintenance.	Cancer discovery	2014	69
24875860	16653	Yang A	Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations.	Cancer discovery	2014	68
24954535	16653	Kapoor A	Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.	Cell	2014	86
25119024	16653	Viale A	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.	Nature	2014	144
25174400	16653	Kasinski AL	A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer.	Oncogene	2015	28
25174708	16653	Schulz MD	High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity.	Nature	2014	47
25261994	16653	Mayers JR	Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development.	Nature medicine	2014	67
25263330	16653	Platt RJ	CRISPR-Cas9 knockin mice for genome editing and cancer modeling.	Cell	2014	179
25339352	16653	Tao S	Oncogenic KRAS confers chemoresistance by upregulating NRF2.	Cancer research	2014	34
25363767	16653	Westcott PM	The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.	Nature	2015	48
25601637	16653	Kong B	A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.	Gut	2016	10
25734337	16653	Grabner B	Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.	Nature communications	2015	18
25843002	16653	von Karstedt S	Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis.	Cancer cell	2015	19
26004068	16653	Whittle MC	RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.	Cell	2015	19
26106858	16653	Melo SA	Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.	Nature	2015	183
26151762	16653	Krah NM	The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma.	eLife	2015	17
26541605	16653	Yun J	Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.	Science	2015	50
26677984	16653	Choi E	Expression of Activated Ras in Gastric Chief Cells of Mice Leads to the Full Spectrum of Metaplastic Lineage Transitions.	Gastroenterology	2016	11
26855149	16653	Ambrogio C	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.	Nature medicine	2016	13
26872698	16653	Pfirschke C	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.	Immunity	2016	25
27089513	16653	Laklai H	Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.	Nature medicine	2016	25
27454043	16653	Conde J	Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model.	Nature materials	2016	12
27799657	16653	Kottakis F	LKB1 loss links serine metabolism to DNA methylation and tumorigenesis.	Nature	2016	11
27821490	16653	Wang X	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.	Cancer research	2017	9
1614537	17246	Oliner JD	Amplification of a gene encoding a p53-associated protein in human sarcomas.	Nature	1992	404
2026149	17246	Fakharzadeh SS	Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.	The EMBO journal	1991	154
7477326	17246	Montes de Oca Luna R	Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.	Nature	1995	431
10995391	17246	Weber JD	p53-independent functions of the p19(ARF) tumor suppressor.	Genes and development	2000	103
11528400	17246	Parant J	Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.	Nature genetics	2001	171
11953423	17246	Gu J	Mutual dependence of MDM2 and MDMX in their functional inactivation of p53.	The Journal of biological chemistry	2002	92
12509446	17246	Mendrysa SM	mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation.	Molecular and cellular biology	2003	77
15989966	17246	Yuan X	Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis.	Molecular cell	2005	96
16354690	17246	Grier JD	Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.	Molecular and cellular biology	2006	63
16391230	17246	Mendrysa SM	Tumor suppression and normal aging in mice with constitutively high p53 activity.	Genes and development	2006	83
16492743	17246	Xiong S	Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.	Proceedings of the National Academy of Sciences of the United States of America	2006	61
16533949	17246	Lengner CJ	Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.	The Journal of cell biology	2006	92
17110929	17246	Gilkes DM	MDMX regulation of p53 response to ribosomal stress.	The EMBO journal	2006	65
17157790	17246	Ringshausen I	Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.	Cancer cell	2006	83
17526734	17246	Terzian T	Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.	Molecular and cellular biology	2007	56
17936560	17246	Itahana K	Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.	Cancer cell	2007	99
18204439	17246	Yang JY	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.	Nature cell biology	2008	197
19450511	17246	Kruse JP	Modes of p53 regulation.	Cell	2009	507
19543236	17246	Lee JT	The multiple levels of regulation by p53 ubiquitination.	Cell death and differentiation	2010	82
20193641	17246	Amaral JD	The role of p53 in apoptosis.	Discovery medicine	2010	48
20832750	17246	Post SM	A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.	Cancer cell	2010	48
21040902	17246	Abbas HA	Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity.	Cell stem cell	2010	47
21730132	17246	Pant V	Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability.	Proceedings of the National Academy of Sciences of the United States of America	2011	52
24583641	17246	Phesse TJ	Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo.	Cell death and differentiation	2014	23
25145672	17246	Wang S	SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.	Cancer research	2014	31
25799988	17246	Jiang L	Ferroptosis as a p53-mediated activity during tumour suppression.	Nature	2015	81
7628020	17685	de Wind N	Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer.	Cell	1995	205
14744764	17685	Lin DP	An Msh2 point mutation uncouples DNA mismatch repair and apoptosis.	Cancer research	2004	74
15126346	17685	Xie Y	Deficiencies in mouse Myh and Ogg1 result in tumor predisposition and G to T mutations in codon 12 of the K-ras oncogene in lung tumors.	Cancer research	2004	72
17723178	17685	Clapper ML	Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions.	Acta pharmacologica Sinica	2007	56
18426915	17685	Wu Y	FANCJ helicase defective in Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend genomic stability.	Molecular and cellular biology	2008	144
20940147	17685	McDonald DA	A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease.	Human molecular genetics	2011	35
25036629	17685	Belcheva A	Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells.	Cell	2014	51
27020939	17685	Healey KR	Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance.	Nature communications	2016	18
11278868	17829	Schroeder JA	Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland.	The Journal of biological chemistry	2001	90
20703838	17829	Kim YS	Intestinal goblet cells and mucins in health and disease: recent insights and progress.	Current gastroenterology reports	2010	146
21558393	17829	Besmer DM	Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.	Cancer research	2011	41
22171012	17829	Lakshminarayanan V	Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.	Proceedings of the National Academy of Sciences of the United States of America	2012	60
23303343	17829	Horm TM	MUC1 and metastatic cancer: expression, function and therapeutic targeting.	Cell adhesion and migration	2013	28
6488314	17869	Stewart TA	Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes.	Cell	1984	199
7784172	17869	Littlewood TD	A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.	Nucleic acids research	1995	257
10488335	17869	Felsher DW	Reversible tumorigenesis by MYC in hematopoietic lineages.	Molecular cell	1999	272
10541552	17869	Eischen CM	Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.	Genes and development	1999	266
10557294	17869	Iritani BM	c-Myc enhances protein synthesis and cell size during B lymphocyte development.	Proceedings of the National Academy of Sciences of the United States of America	1999	104
11369200	17869	Arnold I	c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny.	Current biology 	2001	101
12098700	17869	Jain M	Sustained loss of a neoplastic phenotype by brief inactivation of MYC.	Science	2002	170
12185366	17869	Mikkers H	High-throughput retroviral tagging to identify components of specific signaling pathways in cancer.	Nature genetics	2002	130
12441288	17869	Kenney AM	Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors.	Development	2003	159
14522256	17869	Ellwood-Yen K	Myc-driven murine prostate cancer shares molecular features with human prostate tumors.	Cancer cell	2003	240
15825089	17869	Mariadason JM	Gene expression profiling of intestinal epithelial cell maturation along the crypt-villus axis.	Gastroenterology	2005	66
16751266	17869	Klinakis A	Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice.	Proceedings of the National Academy of Sciences of the United States of America	2006	77
17235397	17869	Amaravadi RK	Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.	The Journal of clinical investigation	2007	373
18066065	17869	Chang TC	Widespread microRNA repression by Myc contributes to tumorigenesis.	Nature genetics	2008	439
18314482	17869	Huppi K	The identification of microRNAs in a genomically unstable region of human chromosome 8q24.	Molecular cancer research 	2008	55
18713946	17869	Sander S	MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.	Blood	2008	116
18716624	17869	Soucek L	Modelling Myc inhibition as a cancer therapy.	Nature	2008	237
19011615	17869	Barna M	Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency.	Nature	2008	121
19745813	17869	Lin CH	Myc-regulated microRNAs attenuate embryonic stem cell differentiation.	The EMBO journal	2009	76
20364083	17869	Ahuja P	Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice.	The Journal of clinical investigation	2010	44
20519624	17869	den Hollander J	Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.	Blood	2010	63
20627891	17869	Wasserman NF	An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer.	Genome research	2010	81
20643922	17869	Yang D	Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase.	Proceedings of the National Academy of Sciences of the United States of America	2010	61
22039435	17869	Ji H	Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation.	PloS one	2011	47
23431158	17869	Ischenko I	Direct reprogramming by oncogenic Ras and Myc.	Proceedings of the National Academy of Sciences of the United States of America	2013	28
24210820	17869	Shin J	SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease.	Cell reports	2013	39
24360274	17869	Kieffer-Kwon KR	Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation.	Cell	2013	99
24518206	17869	Affer M	Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.	Leukemia	2014	42
24686169	17869	Jin R	NF-κB gene signature predicts prostate cancer progression.	Cancer research	2014	26
25043028	17869	Sabò A	Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.	Nature	2014	94
25043044	17869	Tseng YY	PVT1 dependence in cancer with MYC copy-number increase.	Nature	2014	93
25130259	17869	Annibali D	Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis.	Nature communications	2014	29
25369933	17869	Yashiro-Ohtani Y	Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2014	29
25471879	17869	Kumar RM	Deconstructing transcriptional heterogeneity in pluripotent stem cells.	Nature	2014	72
26735015	17869	Wilhelm K	FOXO1 couples metabolic activity and growth state in the vascular endothelium.	Nature	2016	24
26966191	17869	Casey SC	MYC regulates the antitumor immune response through CD47 and PD-L1.	Science	2016	37
7920653	18015	Jacks T	Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.	Nature genetics	1994	159
7926784	18015	Brannan CI	Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.	Genes and development	1994	133
9214616	18015	Weiss WA	Targeted expression of MYCN causes neuroblastoma in transgenic mice.	The EMBO journal	1997	195
10591652	18015	Cichowski K	Mouse models of tumor development in neurofibromatosis type 1.	Science	1999	113
10591653	18015	Vogel KS	Mouse tumor model for neurofibromatosis type 1.	Science	1999	98
10973261	18015	Reilly KM	Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.	Nature genetics	2000	94
11297510	18015	Zhu Y	Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain.	Genes and development	2001	178
11793011	18015	Costa RM	Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1.	Nature	2002	140
11988578	18015	Zhu Y	Neurofibromas in NF1: Schwann cell origin and role of tumor environment.	Science	2002	158
12077339	18015	Bajenaru ML	Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.	Molecular and cellular biology	2002	95
14695164	18015	Bajenaru ML	Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.	Cancer research	2003	94
15805275	18015	Dasgupta B	Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.	Cancer research	2005	79
15937108	18015	Johannessen CM	The NF1 tumor suppressor critically regulates TSC2 and mTOR.	Proceedings of the National Academy of Sciences of the United States of America	2005	150
16098465	18015	Zhu Y	Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.	Cancer cell	2005	152
16271875	18015	Li W	The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.	Current biology 	2005	101
17105749	18015	Ferner RE	Guidelines for the diagnosis and management of individuals with neurofibromatosis 1.	Journal of medical genetics	2007	93
17362838	18015	Ferner RE	Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective.	The Lancet. Neurology	2007	64
17400655	18015	Daginakatte GC	Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth.	Human molecular genetics	2007	69
18164202	18015	Johannessen CM	TORC1 is essential for NF1-associated malignancies.	Current biology 	2008	66
18242513	18015	Joseph NM	The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.	Cancer cell	2008	52
18451155	18015	Kwon CH	Pten haploinsufficiency accelerates formation of high-grade astrocytomas.	Cancer research	2008	91
18984165	18015	Cui Y	Neurofibromin regulation of ERK signaling modulates GABA release and learning.	Cell	2008	118
19727076	18015	Lauchle JO	Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.	Nature	2009	49
20876733	18015	Lee DY	Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.	Genes and development	2010	47
21737130	18015	Liu C	Mosaic analysis with double markers reveals tumor cell of origin in glioma.	Cell	2011	158
22789544	18015	Lee DY	Innate neural stem cell heterogeneity determines the patterning of glioma formation in children.	Cancer cell	2012	36
23221337	18015	Chang T	Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.	The Journal of clinical investigation	2013	40
23221341	18015	Jessen WJ	MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.	The Journal of clinical investigation	2013	66
23434321	18015	Mo W	CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.	Cell	2013	48
24535670	18015	de Bruin EC	Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.	Cancer discovery	2014	33
25119042	18015	De Raedt T	PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.	Nature	2014	63
26067104	18015	Zuckermann M	Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling.	Nature communications	2015	31
9240432	18024	Itoh K	An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.	Biochemical and biophysical research communications	1997	704
11248092	18024	Ramos-Gomez M	Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice.	Proceedings of the National Academy of Sciences of the United States of America	2001	271
11694642	18024	Talalay P	Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism.	The Journal of nutrition	2001	89
11940647	18024	Kwak MK	Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter.	Molecular and cellular biology	2002	113
12032331	18024	Fahey JW	Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzoapyrene-induced stomach tumors.	Proceedings of the National Academy of Sciences of the United States of America	2002	134
12506115	18024	Kwak MK	Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival.	The Journal of biological chemistry	2003	180
15374950	18024	Iida K	Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis.	Cancer research	2004	92
16487040	18024	Cho HY	Nrf2 defends the lung from oxidative stress.	Antioxidants and redox signaling	2006	124
16489057	18024	Yates MS	Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oylimidazole.	Cancer research	2006	69
16507366	18024	Padmanabhan B	Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.	Molecular cell	2006	179
16516379	18024	Hu R	Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice.	Cancer letters	2006	69
16912211	18024	Xu C	Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2.	Cancer research	2006	103
17178849	18024	Khor TO	Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis.	Cancer research	2006	112
17562481	18024	Aleksunes LM	Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease.	Toxicologic pathology	2007	84
17631644	18024	Osburn WO	Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment.	International journal of cancer	2007	62
18287083	18024	Pearson KJ	Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction.	Proceedings of the National Academy of Sciences of the United States of America	2008	76
18316592	18024	Ohta T	Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.	Cancer research	2008	158
18372916	18024	Frohlich DA	The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis.	Oncogene	2008	56
18694732	18024	Li W	Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis.	Biochemical pharmacology	2008	96
19138955	18024	Khor TO	Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer.	Cancer prevention research	2008	73
19646463	18024	Cho HY	Nrf2 protects against airway disorders.	Toxicology and applied pharmacology	2010	58
19914374	18024	Chowdhry S	Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis.	Free radical biology and medicine	2010	51
20062804	18024	Yu S	Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice.	PloS one	2010	60
20300512	18024	Segal BH	NADPH oxidase limits innate immune responses in the lungs in mice.	PloS one	2010	54
20439747	18024	Ahn YH	Electrophilic tuning of the chemoprotective natural product sulforaphane.	Proceedings of the National Academy of Sciences of the United States of America	2010	43
20446773	18024	Singh A	Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance.	Antioxidants and redox signaling	2010	41
20486765	18024	Hu R	Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory.	Antioxidants and redox signaling	2010	47
20966874	18024	Jung KA	The Nrf2 system as a potential target for the development of indirect antioxidants.	Molecules	2010	70
21057541	18024	Martín-Montalvo A	NRF2, cancer and calorie restriction.	Oncogene	2011	40
21369766	18024	Slocum SL	Nrf2: control of sensitivity to carcinogens.	Archives of toxicology	2011	53
21482715	18024	Inami Y	Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells.	The Journal of cell biology	2011	131
21734707	18024	DeNicola GM	Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.	Nature	2011	376
21787756	18024	Khor TO	Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation.	Biochemical pharmacology	2011	39
22966037	18024	Ma Q	Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2.	Pharmacological reviews	2012	51
23041058	18024	Lee JH	Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression.	Pharmacology and therapeutics	2013	33
23610445	18024	Satoh H	Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis.	Cancer research	2013	43
23921124	18024	Singh A	Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis.	The Journal of clinical investigation	2013	59
24206218	18024	Ludtmann MH	Nrf2 affects the efficiency of mitochondrial fatty acid oxidation.	The Biochemical journal	2014	24
24441674	18024	Su ZY	Requirement and epigenetics reprogramming of Nrf2 in suppression of tumor promoter TPA-induced mouse skin cell transformation by sulforaphane.	Cancer prevention research	2014	29
24637114	18024	Pekovic-Vaughan V	The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis.	Genes and development	2014	37
24948812	18024	Wang X	Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord barriers.	The Journal of neuroscience 	2014	22
24958099	18024	Meakin PJ	Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance.	Molecular and cellular biology	2014	22
15716345	18109	Okubo T	Nmyc plays an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation and differentiation.	Development	2005	102
15843407	18109	Cai CL	T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis.	Development	2005	66
16413481	18109	Hallikas O	Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity.	Cell	2006	196
18488021	18109	Zhao X	The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein.	Nature cell biology	2008	74
20478998	18109	Swartling FJ	Pleiotropic role for MYCN in medulloblastoma.	Genes and development	2010	54
21698133	18109	Marshall GM	SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability.	PLoS genetics	2011	41
22624711	18109	Swartling FJ	Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.	Cancer cell	2012	56
23042116	18109	Molenaar JJ	LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.	Nature genetics	2012	84
23695022	18109	Pasquier E	β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma.	British journal of cancer	2013	31
23733953	18109	Zirath H	MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells.	Proceedings of the National Academy of Sciences of the United States of America	2013	50
23792191	18109	Brockmann M	Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.	Cancer cell	2013	53
24297863	18109	Bandopadhayay P	BET bromodomain inhibition of MYC-amplified medulloblastoma.	Clinical cancer research 	2014	64
26631615	18109	Henssen A	Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.	Clinical cancer research 	2016	16
8642337	18128	Pear WS	Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.	The Journal of experimental medicine	1996	178
10367900	18128	Radtke F	Deficient T cell fate specification in mice with an induced inactivation of Notch1.	Immunity	1999	313
11895769	18128	Stier S	Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome.	Blood	2002	101
12509463	18128	Weng AP	Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling.	Molecular and cellular biology	2003	141
12590261	18128	Nicolas M	Notch1 functions as a tumor suppressor in mouse skin.	Nature genetics	2003	269
15535842	18128	Dontu G	Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells.	Breast cancer research 	2004	222
16166587	18128	O'Neil J	Activating Notch1 mutations in mouse models of T-ALL.	Blood	2006	82
16354692	18128	Dumortier A	Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice.	Molecular and cellular biology	2006	63
16612405	18128	Grabher C	Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia.	Nature reviews. Cancer	2006	126
16847353	18128	Weng AP	c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma.	Genes and development	2006	264
16954387	18128	Sharma VM	Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc.	Molecular and cellular biology	2006	97
17353266	18128	Yugawa T	Regulation of Notch1 gene expression by p53 in epithelial cells.	Molecular and cellular biology	2007	68
18677410	18128	Chiang MY	Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia.	The Journal of clinical investigation	2008	90
19228774	18128	Engin F	Notch signaling contributes to the pathogenesis of human osteosarcomas.	Human molecular genetics	2009	58
19573812	18128	Demehri S	Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment.	Cancer cell	2009	86
19907488	18128	Moellering RE	Direct inhibition of the NOTCH transcription factor complex.	Nature	2009	225
20393564	18128	Wu Y	Therapeutic antibody targeting of individual Notch receptors.	Nature	2010	195
20624967	18128	Mazur PK	Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2010	65
20967796	18128	Aster JC	Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies.	The Journal of pathology	2011	60
21266774	18128	Liu Z	Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice.	The Journal of clinical investigation	2011	52
21285514	18128	Varnum-Finney B	Notch2 governs the rate of generation of mouse long- and short-term repopulating stem cells.	The Journal of clinical investigation	2011	45
21737748	18128	Wang H	Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	83
21795743	18128	Outtz HH	Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice.	Blood	2011	37
21804540	18128	Pajvani UB	Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner.	Nature medicine	2011	42
23727022	18128	Zender S	A critical role for notch signaling in the formation of cholangiocellular carcinomas.	Cancer cell	2013	38
25038826	18128	Bi P	Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity.	Nature medicine	2014	45
25301628	18128	Magnusson JP	A latent neurogenic program in astrocytes regulated by Notch signaling in the mouse.	Science	2014	53
25538079	18128	Martz CA	Systematic identification of signaling pathways with potential to confer anticancer drug resistance.	Science signaling	2014	38
26390244	18128	Herranz D	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.	Nature medicine	2015	25
11015443	18566	Freeman GJ	Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.	The Journal of experimental medicine	2000	735
12421930	18566	Yamazaki T	Expression of programmed death 1 ligands by murine T cells and APC.	Journal of immunology	2002	212
15827960	18566	Augello A	Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway.	European journal of immunology	2005	121
17404099	18566	Nomi T	Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.	Clinical cancer research 	2007	188
19234176	18566	Parekh VV	PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.	Journal of immunology	2009	60
19417208	18566	Zhang L	PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.	Blood	2009	82
19420358	18566	Mumprecht S	Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.	Blood	2009	55
22797302	18566	Erickson JJ	Viral acute lower respiratory infections impair CD8+ T cells through PD-1.	The Journal of clinical investigation	2012	41
23462419	18566	Zeng J	Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.	International journal of radiation oncology, biology, physics	2013	108
23975756	18566	Duraiswamy J	Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.	Cancer research	2013	69
24240160	18566	Okazaki T	A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.	Nature immunology	2013	106
24502656	18566	Lu L	Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.	Journal of translational medicine	2014	23
26034050	18566	Odorizzi PM	Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells.	The Journal of experimental medicine	2015	30
26883990	18566	Koyama S	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.	Nature communications	2016	55
27446497	18566	Hettich M	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.	Theranostics	2016	16
27789795	18566	Pauken KE	Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.	Science	2016	25
9108099	18669	Schinkel AH	Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.	Proceedings of the National Academy of Sciences of the United States of America	1997	118
19800114	18669	Patil YB	The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.	Biomaterials	2010	50
19956709	18669	Ghaemmaghami S	Continuous quinacrine treatment results in the formation of drug-resistant prions.	PLoS pathogens	2009	46
20304939	18669	Kodaira H	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	The Journal of pharmacology and experimental therapeutics	2010	53
20421331	18669	Agarwal S	Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.	The Journal of pharmacology and experimental therapeutics	2010	49
20876799	18669	Mi YJ	Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.	Cancer research	2010	47
21351087	18669	Tang SC	Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.	International journal of cancer	2012	36
22778859	18669	Kannan P	The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).	ACS chemical neuroscience	2011	40
15549107	19126	Singh SK	Identification of human brain tumour initiating cells.	Nature	2004	1811
17084552	19126	Blazek ER	Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia.	International journal of radiation oncology, biology, physics	2007	57
17122771	19126	Ricci-Vitiani L	Identification and expansion of human colon-cancer-initiating cells.	Nature	2007	1050
17483311	19126	Beier D	CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.	Cancer research	2007	313
18049477	19126	Eramo A	Identification and expansion of the tumorigenic lung cancer stem cell population.	Cell death and differentiation	2008	420
18535669	19126	Khan ZA	Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice.	The Journal of clinical investigation	2008	73
18663533	19126	Haraguchi N	CD133+CD44+ population efficiently enriches colon cancer initiating cells.	Annals of surgical oncology	2008	63
19020659	19126	Wang J	c-Myc is required for maintenance of glioma cancer stem cells.	PloS one	2008	116
19243384	19126	Tchoghandjian A	A2B5 cells from human glioblastoma have cancer stem cell properties.	Brain pathology	2010	44
20620237	19126	Wang CH	Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody.	Nanomedicine 	2011	40
21112564	19126	Ma S	miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.	Cell stem cell	2010	103
23307586	19126	Brescia P	CD133 is essential for glioblastoma stem cell maintenance.	Stem cells	2013	37
25200065	19126	Zhang D	Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.	Molecular cancer	2014	22
15380514	19206	Romer JT	Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice.	Cancer cell	2004	142
17287253	19206	Moraes RC	Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia.	Development	2007	82
17452975	19206	Lee Y	Loss of suppressor-of-fused function promotes tumorigenesis.	Oncogene	2007	62
18711141	19206	Mancuso M	Oncogenic bystander radiation effects in Patched heterozygous mouse cerebellum.	Proceedings of the National Academy of Sciences of the United States of America	2008	73
21215705	19206	Wang GY	Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice.	Cancer cell	2011	54
21316601	19206	Rubin BP	Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma.	Cancer cell	2011	62
21321199	19206	Kasper M	Wounding enhances epidermal tumorigenesis by recruiting hair follicle keratinocytes.	Proceedings of the National Academy of Sciences of the United States of America	2011	48
21430703	19206	Skvara H	Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.	The Journal of investigative dermatology	2011	35
9697695	19211	Di Cristofano A	Pten is essential for embryonic development and tumour suppression.	Nature genetics	1998	421
9799734	19211	Suzuki A	High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.	Current biology 	1998	208
9990064	19211	Podsypanina K	Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.	Proceedings of the National Academy of Sciences of the United States of America	1999	267
10497129	19211	Di Cristofano A	Impaired Fas response and autoimmunity in Pten+/- mice.	Science	1999	114
10910075	19211	Stambolic V	High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice.	Cancer research	2000	114
11371355	19211	Suzuki A	T cell-specific loss of Pten leads to defects in central and peripheral tolerance.	Immunity	2001	163
11504907	19211	Podsypanina K	An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.	Proceedings of the National Academy of Sciences of the United States of America	2001	127
11504908	19211	Neshat MS	Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.	Proceedings of the National Academy of Sciences of the United States of America	2001	212
11545734	19211	Stambolic V	Regulation of PTEN transcription by p53.	Molecular cell	2001	208
11726926	19211	Backman SA	Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease.	Nature genetics	2001	132
12163417	19211	Li G	Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland.	Development	2002	83
12620407	19211	Freeman DJ	PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.	Cancer cell	2003	120
14522255	19211	Wang S	Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.	Cancer cell	2003	337
14668450	19211	Li Y	Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells.	Proceedings of the National Academy of Sciences of the United States of America	2003	184
15199412	19211	Horie Y	Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.	The Journal of clinical investigation	2004	153
15261145	19211	Shaw RJ	The LKB1 tumor suppressor negatively regulates mTOR signaling.	Cancer cell	2004	295
15328005	19211	Stiles B	PTENless means more.	Developmental biology	2004	81
15520182	19211	Fraser MM	Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo.	Cancer research	2004	83
16079851	19211	Chen Z	Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.	Nature	2005	592
16169464	19211	Stanger BZ	Pten constrains centroacinar cell expansion and malignant transformation in the pancreas.	Cancer cell	2005	107
16432235	19211	Wang S	Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation.	Proceedings of the National Academy of Sciences of the United States of America	2006	116
16598206	19211	Yilmaz OH	Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.	Nature	2006	453
16633340	19211	Zhang J	PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention.	Nature	2006	295
17418409	19211	Wu R	Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.	Cancer cell	2007	122
17496901	19211	Hernando E	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas.	Nature medicine	2007	76
17515920	19211	Maser RS	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.	Nature	2007	181
17607361	19211	Berquin IM	Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids.	The Journal of clinical investigation	2007	88
17616663	19211	Jiao J	Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.	Cancer research	2007	56
17909629	19211	Yanagi S	Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice.	The Journal of clinical investigation	2007	62
18066063	19211	Saal LH	Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.	Nature genetics	2008	128
18082964	19211	Fraser MM	Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities.	Neuroscience	2008	60
18258752	19211	de la Iglesia N	Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.	Genes and development	2008	110
18322014	19211	Hui ST	Txnip balances metabolic and growth signaling via PTEN disulfide reduction.	Proceedings of the National Academy of Sciences of the United States of America	2008	72
18327259	19211	Xiao C	Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes.	Nature immunology	2008	417
18387000	19211	Huang X	Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.	The Biochemical journal	2008	121
18463637	19211	Guo W	Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation.	Nature	2008	83
18632614	19211	Daikoku T	Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice.	Cancer research	2008	79
18948956	19211	Zheng H	p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.	Nature	2008	237
19185849	19211	Guertin DA	mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.	Cancer cell	2009	143
19261747	19211	Puzio-Kuter AM	Inactivation of p53 and Pten promotes invasive bladder cancer.	Genes and development	2009	89
19326431	19211	Narayanan NK	Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.	International journal of cancer	2009	57
19396168	19211	Carver BS	Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.	Nature genetics	2009	213
19487573	19211	Huse JT	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.	Genes and development	2009	172
19847259	19211	Trimboli AJ	Pten in stromal fibroblasts suppresses mammary epithelial tumours.	Nature	2009	178
19887604	19211	Mulholland DJ	Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model.	Cancer research	2009	80
20197621	19211	Alimonti A	A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.	The Journal of clinical investigation	2010	98
20400965	19211	Alimonti A	Subtle variations in Pten dose determine cancer susceptibility.	Nature genetics	2010	153
21236500	19211	Leslie NR	Non-genomic loss of PTEN function in cancer: not in my genes.	Trends in pharmacological sciences	2011	47
21266353	19211	Carracedo A	PTEN level in tumor suppression: how much is too little?	Cancer research	2011	67
21300890	19211	Cima I	Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2011	42
21430697	19211	Hollander MC	PTEN loss in the continuum of common cancers, rare syndromes and mouse models.	Nature reviews. Cancer	2011	216
21572435	19211	Vitari AC	COP1 is a tumour suppressor that causes degradation of ETS transcription factors.	Nature	2011	49
21575859	19211	Carver BS	Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.	Cancer cell	2011	296
22037217	19211	Bian Y	Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation.	Oncogene	2012	46
22331912	19211	Kim J	High-grade serous ovarian cancer arises from fallopian tube in a mouse model.	Proceedings of the National Academy of Sciences of the United States of America	2012	90
22340597	19211	Choi N	Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation.	Cancer cell	2012	108
22350410	19211	Mulholland DJ	Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.	Cancer research	2012	123
22401813	19211	Garcia-Cao I	Systemic elevation of PTEN induces a tumor-suppressive metabolic state.	Cell	2012	93
22405073	19211	Ortega-Molina A	Pten positively regulates brown adipose function, energy expenditure, and longevity.	Cell metabolism	2012	57
22544933	19211	Liu Y	MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN.	Journal of immunology	2012	65
22859719	19211	Sun ZJ	Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.	Clinical cancer research 	2012	38
22958933	19211	Magee JA	Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression.	Cell stem cell	2012	59
22958934	19211	Kalaitzidis D	mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis.	Cell stem cell	2012	60
23245767	19211	Ortega-Molina A	PTEN in cancer, metabolism, and aging.	Trends in endocrinology and metabolism	2013	29
23313138	19211	Lu TL	Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.	The American journal of pathology	2013	40
23727860	19211	Lunardi A	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.	Nature genetics	2013	39
23749645	19211	Muir K	Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma.	Cancer research	2013	31
23902739	19211	Conley-LaComb MK	PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.	Molecular cancer	2013	28
24630729	19211	McFadden DG	Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.	Cell	2014	56
24670665	19211	Signer RA	Haematopoietic stem cells require a highly regulated protein synthesis rate.	Nature	2014	64
24766807	19211	Papa A	Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function.	Cell	2014	46
24794706	19211	Xu C	Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.	Cancer cell	2014	56
24899687	19211	Guan B	Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.	Journal of the National Cancer Institute	2014	25
25119044	19211	Xue W	CRISPR-mediated direct mutation of cancer genes in the mouse liver.	Nature	2014	111
25446664	19211	Lengyel E	Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.	American journal of obstetrics and gynecology	2015	17
26086867	19211	Wang D	Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses.	Human gene therapy	2015	26
26479035	19211	Zhang L	Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth.	Nature	2015	94
11114892	19645	Sage J	Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization.	Genes and development	2000	202
11114893	19645	Dannenberg JH	Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions.	Genes and development	2000	130
12839925	19645	Flesken-Nikitin A	Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.	Cancer research	2003	94
14522252	19645	Meuwissen R	Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.	Cancer cell	2003	123
15750587	19645	Gonzalo S	Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin.	Nature cell biology	2005	93
16360031	19645	Hill R	Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis.	Cell	2005	112
18559481	19645	Walkley CR	Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease.	Genes and development	2008	117
20551164	19645	van Harn T	Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling.	Genes and development	2010	44
20551166	19645	Coschi CH	Mitotic chromosome condensation mediated by the retinoblastoma protein is tumor-suppressive.	Genes and development	2010	55
20679727	19645	Jiang Z	Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.	The Journal of clinical investigation	2010	57
21665149	19645	Sutherland KD	Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.	Cancer cell	2011	94
21875955	19645	Viatour P	Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway.	The Journal of experimental medicine	2011	57
21983857	19645	Park KS	A crucial requirement for Hedgehog signaling in small cell lung cancer.	Nature medicine	2011	73
23454836	19645	Livi CB	Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors.	Aging	2013	35
10458605	20848	Bromberg JF	Stat3 as an oncogene.	Cell	1999	762
10521404	20848	Chapman RS	Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3.	Genes and development	1999	124
12150892	20848	Lee CK	STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation.	Immunity	2002	82
14979921	20848	Clarkson RW	Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression.	Breast cancer research 	2004	99
15343391	20848	Chan KS	Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis.	The Journal of clinical investigation	2004	132
15735721	20848	Dauer DJ	Stat3 regulates genes common to both wound healing and cancer.	Oncogene	2005	124
15895073	20848	Chiarle R	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.	Nature medicine	2005	124
16288283	20848	Kortylewski M	Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.	Nature medicine	2005	275
17942891	20848	Hussain SF	A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.	Cancer research	2007	73
17982462	20848	Johnen H	Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1.	Nature medicine	2007	68
18154266	20848	Siddiquee KA	An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects.	ACS chemical biology	2007	57
18776941	20848	Kujawski M	Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice.	The Journal of clinical investigation	2008	135
19131594	20848	Wegrzyn J	Function of mitochondrial Stat3 in cellular respiration.	Science	2009	231
19244102	20848	Xin H	Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.	Cancer research	2009	129
19749770	20848	Kortylewski M	In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.	Nature biotechnology	2009	106
19962983	20848	Musteanu M	Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice.	Gastroenterology	2010	45
20038814	20848	Ma J	Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade.	The Journal of clinical investigation	2010	73
20042677	20848	Deng L	A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis.	The American journal of pathology	2010	50
20215508	20848	Barbieri I	Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten.	Cancer research	2010	43
20581311	20848	Zhang H	STAT3 controls myeloid progenitor growth during emergency granulopoiesis.	Blood	2010	49
20884624	20848	Chen KF	Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.	Clinical cancer research 	2010	46
21159818	20848	Tee WW	Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency.	Genes and development	2010	69
23079657	20848	Tye H	STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation.	Cancer cell	2012	47
24019511	20848	Zhang Q	Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727.	The Journal of biological chemistry	2013	33
24412612	20848	Guo X	Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection.	Immunity	2014	32
24681959	20848	Bharadwaj U	Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.	Oncogene	2015	26
24743778	20848	Xiong A	Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.	Cancers	2014	26
27292260	20848	Saini U	Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.	Oncogene	2017	6
14985505	20869	Shaw RJ	The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.	Proceedings of the National Academy of Sciences of the United States of America	2004	483
18227155	20869	Hezel AF	Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms.	Molecular and cellular biology	2008	65
19029933	20869	Hezel AF	LKB1; linking cell structure and tumor suppression.	Oncogene	2008	67
21102522	20869	Algire C	Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.	Oncogene	2011	43
21124451	20869	Gurumurthy S	The Lkb1 metabolic sensor maintains haematopoietic stem cell survival.	Nature	2010	127
21124456	20869	Gan B	Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells.	Nature	2010	131
21266715	20869	Jacob LS	Genome-wide RNAi screen reveals disease-associated genes that are common to Hedgehog and Wnt signaling.	Science signaling	2011	38
23040072	20869	Su X	TAp63 is a master transcriptional regulator of lipid and glucose metabolism.	Cell metabolism	2012	31
25617365	20869	Rao F	Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1.	Proceedings of the National Academy of Sciences of the United States of America	2015	15
26479318	20869	Lin R	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.	Nature cell biology	2015	16
7708687	21803	Sanderson N	Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.	Proceedings of the National Academy of Sciences of the United States of America	1995	130
8421714	21803	Kulkarni AB	Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.	Proceedings of the National Academy of Sciences of the United States of America	1993	416
8752208	21803	Cui W	TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice.	Cell	1996	122
9597127	21803	Letterio JJ	Regulation of immune responses by TGF-beta.	Annual review of immunology	1998	342
9657149	21803	Crawford SE	Thrombospondin-1 is a major activator of TGF-beta1 in vivo.	Cell	1998	277
11590434	21803	Gorelik L	Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.	Nature medicine	2001	156
11920677	21803	Ten Dijke P	Regulation of cell proliferation by Smad proteins.	Journal of cellular physiology	2002	102
12070308	21803	Yang YA	Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.	The Journal of clinical investigation	2002	110
12110587	21803	Yu L	TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses.	The EMBO journal	2002	172
12808151	21803	Siegel PM	Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.	Proceedings of the National Academy of Sciences of the United States of America	2003	131
14764882	21803	Bhowmick NA	TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia.	Science	2004	407
15520202	21803	Uhl M	SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.	Cancer research	2004	89
15664386	21803	Lebrin F	TGF-beta receptor function in the endothelium.	Cardiovascular research	2005	122
15820682	21803	Yamashita M	Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation.	Cell	2005	94
15937546	21803	Han G	Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis.	The Journal of clinical investigation	2005	69
16186184	21803	Ghiringhelli F	Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.	The Journal of experimental medicine	2005	169
16230475	21803	Ghiringhelli F	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.	The Journal of experimental medicine	2005	153
16286245	21803	Thomas DA	TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.	Cancer cell	2005	184
17080199	21803	Tesseur I	Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology.	The Journal of clinical investigation	2006	83
17724470	21803	Gal A	Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis.	Oncogene	2008	74
17898001	21803	Roarty K	Wnt5a is required for proper mammary gland development and TGF-beta-mediated inhibition of ductal growth.	Development	2007	66
18310502	21803	Oka M	Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis.	Blood	2008	59
18506891	21803	Coulouarn C	Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.	Hepatology	2008	77
18593877	21803	Vidal B	Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway.	Genes and development	2008	68
18849330	21803	Clavin NW	TGF-beta1 is a negative regulator of lymphatic regeneration during wound repair.	American journal of physiology. Heart and circulatory physiology	2008	61
19109155	21803	Li H	Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.	Journal of immunology	2009	165
19556507	21803	Wandzioch E	Dynamic signaling network for the specification of embryonic pancreas and liver progenitors.	Science	2009	87
20130650	21803	Naka K	TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.	Nature	2010	141
20227040	21803	Reimann M	Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence.	Cancer cell	2010	42
20442777	21803	Bandyopadhyay A	Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.	PloS one	2010	47
20471291	21803	Ouyang W	Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development.	Immunity	2010	67
20810549	21803	Moses H	TGF-beta biology in mammary development and breast cancer.	Cold Spring Harbor perspectives in biology	2011	70
21056998	21803	Avraham T	Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair.	The American journal of pathology	2010	57
21987723	21803	Schliekelman MJ	Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer.	Cancer research	2011	48
22028490	21803	Bouquet F	TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.	Clinical cancer research 	2011	36
22238361	21803	Leight JL	Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial-mesenchymal transition.	Molecular biology of the cell	2012	84
22664874	21803	Ye XZ	Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway.	Journal of immunology	2012	63
22693253	21803	Hardee ME	Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.	Cancer research	2012	42
23153532	21803	Calon A	Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation.	Cancer cell	2012	132
23391818	21803	Yang L	Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.	Gastroenterology	2013	27
23868260	21803	Wang X	LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling.	Nature	2013	39
23884466	21803	Frischmeyer-Guerrerio PA	TGFβ receptor mutations impose a strong predisposition for human allergic disease.	Science translational medicine	2013	33
24576072	21803	Brockhausen J	miR-181a mediates TGF-β-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer.	Liver international 	2015	19
24792119	21803	Sun D	Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal.	Cell stem cell	2014	73
24892648	21803	Fan QM	Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma.	Cancer letters	2014	51
25605728	21803	Richards EJ	Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β: LncRNA-hit-mediated TGFβ-induced epithelial to mesenchymal transition in mammary epithelia.	The Journal of biological chemistry	2015	25
25644060	21803	Raimondo S	Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism.	Cell communication and signaling 	2015	19
25739764	21803	Hatfield SM	Immunological mechanisms of the antitumor effects of supplemental oxygenation.	Science translational medicine	2015	37
25858148	21803	Vanpouille-Box C	TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.	Cancer research	2015	25
26109568	21803	Bravi L	Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice.	Proceedings of the National Academy of Sciences of the United States of America	2015	15
26884601	21803	Viel S	TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.	Science signaling	2016	13
10411544	22035	Ashkenazi A	Safety and antitumor activity of recombinant soluble Apo2 ligand.	The Journal of clinical investigation	1999	397
10802713	22035	Jo M	Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand.	Nature medicine	2000	123
11561060	22035	Kelley SK	Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.	The Journal of pharmacology and experimental therapeutics	2001	92
11801676	22035	Cretney E	Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.	Journal of immunology	2002	120
17908999	22035	Corsten MF	MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas.	Cancer research	2007	119
20388793	22035	Grisendi G	Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.	Cancer research	2010	50
21084267	22035	Bagci-Onder T	A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models.	Cancer research	2011	41
24789911	22035	Condamine T	ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.	The Journal of clinical investigation	2014	31
12567186	22059	Hemann MT	An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.	Nature genetics	2003	98
14561707	22059	Zhang H	Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.	The Journal of clinical investigation	2003	197
14702042	22059	Liu G	Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice.	Nature genetics	2004	90
15924142	22059	Christophorou MA	Temporal dissection of p53 function in vitro and in vivo.	Nature genetics	2005	69
16200064	22059	Dickins RA	Probing tumor phenotypes using stable and regulated synthetic microRNA precursors.	Nature genetics	2005	215
16286925	22059	Sablina AA	The antioxidant function of the p53 tumor suppressor.	Nature medicine	2005	283
18953354	22059	Butelli E	Enrichment of tomato fruit with health-promoting anthocyanins by expression of select transcription factors.	Nature biotechnology	2008	135
19122659	22059	Marumoto T	Development of a novel mouse glioma model using lentiviral vectors.	Nature medicine	2009	106
19556538	22059	Allton K	Trim24 targets endogenous p53 for degradation.	Proceedings of the National Academy of Sciences of the United States of America	2009	60
19668189	22059	Marión RM	A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity.	Nature	2009	372
19776746	22059	Donehower LA	20 years studying p53 functions in genetically engineered mice.	Nature reviews. Cancer	2009	68
20018721	22059	Morton JP	Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	129
20124728	22059	Hirota Y	Uterine-specific p53 deficiency confers premature uterine senescence and promotes preterm birth in mice.	The Journal of clinical investigation	2010	58
21150899	22059	Gibson P	Subtypes of medulloblastoma have distinct developmental origins.	Nature	2010	189
22340591	22059	Kawauchi D	A mouse model of the most aggressive subgroup of human medulloblastoma.	Cancer cell	2012	82
22666537	22059	Bornachea O	EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours.	Scientific reports	2012	33
23650262	22059	Huo Y	Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer.	Cancer discovery	2013	32
23685747	22059	Rahrmann EP	Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.	Nature genetics	2013	49
24298059	22059	Malina A	Repurposing CRISPR/Cas9 for in situ functional assays.	Genes and development	2013	35
24390428	22059	Gilmartin AG	Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.	Nature chemical biology	2014	26
25119037	22059	Van Nostrand JL	Inappropriate p53 activation during development induces features of CHARGE syndrome.	Nature	2014	27
25487151	22059	Wong TN	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.	Nature	2015	72
25732831	22059	Aubrey BJ	An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo.	Cell reports	2015	25
26269570	22059	Miosge LA	Comparison of predicted and actual consequences of missense mutations.	Proceedings of the National Academy of Sciences of the United States of America	2015	30
10491404	22084	Onda H	Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background.	The Journal of clinical investigation	1999	109
11875047	22084	Kwiatkowski DJ	A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.	Human molecular genetics	2002	210
16904612	22084	Sodhi A	The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.	Cancer cell	2006	65
18342602	22084	Ozcan U	Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis.	Molecular cell	2008	158
18568033	22084	Ehninger D	Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.	Nature medicine	2008	255
20534473	22084	Young DM	Altered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism.	Proceedings of the National Academy of Sciences of the United States of America	2010	48
21062901	22084	Zeng LH	Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.	Human molecular genetics	2011	62
23123587	22084	Reith RM	Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex.	Neurobiology of disease	2013	34
23250422	22084	Sato A	Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.	Nature communications	2012	32
2478587	22339	Connolly DT	Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.	The Journal of clinical investigation	1989	201
8602242	22339	Ferrara N	Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene.	Nature	1996	639
8962129	22339	Yuan F	Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.	Proceedings of the National Academy of Sciences of the United States of America	1996	151
9753319	22339	Fukumura D	Tumor induction of VEGF promoter activity in stromal cells.	Cell	1998	186
9774334	22339	Mohammadi M	Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.	The EMBO journal	1998	111
10416597	22339	Gorski DH	Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.	Cancer research	1999	169
11034104	22339	Lee CG	Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.	Cancer research	2000	115
11507045	22339	Fukumura D	Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.	Cancer research	2001	87
12086877	22339	Inoue M	VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis.	Cancer cell	2002	83
12381667	22339	Ruhrberg C	Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis.	Genes and development	2002	235
12461084	22339	Nagy JA	Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.	The Journal of experimental medicine	2002	117
15705858	22339	Gerber HP	Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.	Cancer research	2005	123
15809353	22339	Hirakawa S	VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.	The Journal of experimental medicine	2005	169
16172168	22339	Kamba T	VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.	American journal of physiology. Heart and circulatory physiology	2006	194
17016557	22339	Mancuso MR	Rapid vascular regrowth in tumors after reversal of VEGF inhibition.	The Journal of clinical investigation	2006	206
17606728	22339	Dickson PV	Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.	Clinical cancer research 	2007	116
17719546	22339	Lee S	Autocrine VEGF signaling is required for vascular homeostasis.	Cell	2007	286
18293091	22339	Nagy JA	Vascular permeability, vascular hyperpermeability and angiogenesis.	Angiogenesis	2008	125
18337603	22339	Eremina V	VEGF inhibition and renal thrombotic microangiopathy.	The New England journal of medicine	2008	294
18495668	22339	Guo X	Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer.	The Journal of biological chemistry	2008	54
18650835	22339	Bergers G	Modes of resistance to anti-angiogenic therapy.	Nature reviews. Cancer	2008	725
18766380	22339	Crawford Y	VEGF inhibition: insights from preclinical and clinical studies.	Cell and tissue research	2009	53
18997773	22339	Stockmann C	Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis.	Nature	2008	140
19036702	22339	Klement GL	Platelets actively sequester angiogenesis regulators.	Blood	2009	64
19249680	22339	Pàez-Ribes M	Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.	Cancer cell	2009	665
19249681	22339	Ebos JM	Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.	Cancer cell	2009	483
19906640	22339	Nowak DG	Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.	The Journal of biological chemistry	2010	69
20023634	22339	Kienast Y	Real-time imaging reveals the single steps of brain metastasis formation.	Nature medicine	2010	188
20033380	22339	Hellberg C	PDGF and vessel maturation.	Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer	2010	53
20167811	22339	de Groot JF	Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.	Neuro-oncology	2010	156
20490982	22339	Nagy JA	Heterogeneity of the tumor vasculature.	Seminars in thrombosis and hemostasis	2010	58
20824063	22339	Pereira ER	Transcriptional and post-transcriptional regulation of proangiogenic factors by the unfolded protein response.	PloS one	2010	45
20953557	22339	Meister J	miR-126 and miR-126*: new players in cancer.	TheScientificWorldJournal	2010	56
21102434	22339	Ricci-Vitiani L	Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.	Nature	2010	321
21385942	22339	Licht T	Reversible modulations of neuronal plasticity by VEGF.	Proceedings of the National Academy of Sciences of the United States of America	2011	48
22012397	22339	Beck B	A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours.	Nature	2011	107
22110210	22339	Zhang T	Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression.	Anticancer research	2011	37
22262122	22339	Linde N	Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages.	The Journal of pathology	2012	31
22434866	22339	Mackenzie F	Diverse roles for VEGF-A in the nervous system.	Development	2012	52
22450551	22339	Maes C	Hypoxia-driven pathways in bone development, regeneration and disease.	Nature reviews. Rheumatology	2012	41
22508695	22339	Sitohy B	Anti-VEGF/VEGFR therapy for cancer: reassessing the target.	Cancer research	2012	77
23804423	22339	Piao Y	Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.	Clinical cancer research 	2013	45
24203759	22339	Liu Y	Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development.	Protein and cell	2013	30
24746698	22339	Karali E	VEGF Signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress.	Molecular cell	2014	35
25362254	22339	Kikuchi R	An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease.	Nature medicine	2014	28
26336827	22339	Yan JJ	MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1.	Oncotarget	2015	16
9850061	26357	Allikmets R	A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.	Cancer research	1998	115
12429862	26357	Jonker JW	The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.	Proceedings of the National Academy of Sciences of the United States of America	2002	124
15044468	26357	Krishnamurthy P	The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.	The Journal of biological chemistry	2004	148
17975156	26357	de Vries NA	P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.	Clinical cancer research 	2007	65
23014761	26357	Agarwal S	Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.	Drug metabolism and disposition	2013	35
16651429	30951	Yang H	Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice.	Cancer research	2006	135
17548809	30951	Zhao M	Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	87
22042970	30951	Chen Y	2-(3-{1-Carboxy-5-(6-18Ffluoro-pyridine-3-carbonyl)-amino-pentyl}-ureido)-pentanedioic acid, 18FDCFPyL, a PSMA-based PET imaging agent for prostate cancer.	Clinical cancer research 	2011	39
22094252	30951	Tan J	CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis.	Cancer cell	2011	42
15899815	109880	Knauf JA	Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.	Cancer research	2005	82
15947100	109880	Xing M	BRAF mutation in thyroid cancer.	Endocrine-related cancer	2005	200
17299132	109880	Dankort D	A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.	Genes and development	2007	140
17510423	109880	Ji H	Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.	Cancer research	2007	66
18172275	109880	Haass NK	The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.	Clinical cancer research 	2008	77
18927438	109880	Kearney L	Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.	Blood	2009	52
19282848	109880	Dankort D	Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.	Nature genetics	2009	299
19345328	109880	Dhomen N	Oncogenic Braf induces melanocyte senescence and melanoma in mice.	Cancer cell	2009	168
19492075	109880	Jaiswal BS	Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.	PloS one	2009	50
20141835	109880	Heidorn SJ	Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.	Cell	2010	378
21220306	109880	Franco AT	Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.	Proceedings of the National Academy of Sciences of the United States of America	2011	48
21383698	109880	Knauf JA	Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.	Oncogene	2011	41
21388974	109880	Cantwell-Dorris ER	BRAFV600E: implications for carcinogenesis and molecular therapy.	Molecular cancer therapeutics	2011	52
21514245	109880	Blasco RB	c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.	Cancer cell	2011	77
21638088	109880	Capper D	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.	Acta neuropathologica	2011	74
22000016	109880	Karreth FA	In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.	Cell	2011	180
22084396	109880	Hoeflich KP	Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.	Cancer research	2012	44
22169110	109880	Packer LM	Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.	Cancer cell	2011	37
22172720	109880	Damsky WE	β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.	Cancer cell	2011	90
22392911	109880	Migliardi G	Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.	Clinical cancer research 	2012	43
22576211	109880	Martin MJ	Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.	Cancer discovery	2012	31
22628411	109880	Collisson EA	A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.	Cancer discovery	2012	56
22693252	109880	Koya RC	BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.	Cancer research	2012	60
22891351	109880	Couto JP	STAT3 negatively regulates thyroid tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2012	37
23123854	109880	Mitra D	An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.	Nature	2012	78
23171796	109880	Maertens O	Elucidating distinct roles for NF1 in melanomagenesis.	Cancer discovery	2013	50
23204132	109880	Liu C	BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.	Clinical cancer research 	2013	78
23249624	109880	Mittapalli RK	Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.	The Journal of pharmacology and experimental therapeutics	2013	25
23454771	109880	Knight DA	Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.	The Journal of clinical investigation	2013	68
23563312	109880	Hanna SC	HIF1α and HIF2α independently activate SRC to promote melanoma metastases.	The Journal of clinical investigation	2013	40
23583981	109880	Zhang J	Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.	Nature genetics	2013	126
23845441	109880	Rad R	A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.	Cancer cell	2013	30
24095280	109880	Shen CH	Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.	Molecular cell	2013	26
24145418	109880	Yuan P	Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.	Proceedings of the National Academy of Sciences of the United States of America	2013	51
24247719	109880	Mok S	Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.	Cancer research	2014	54
24362353	109880	Strohecker AM	Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism.	Autophagy	2014	21
24477002	109880	Sayin VI	Antioxidants accelerate lung cancer progression in mice.	Science translational medicine	2014	115
24711431	109880	McFadden DG	p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	23
24717435	109880	Brady DC	Copper is required for oncogenic BRAF signalling and tumorigenesis.	Nature	2014	47
24746818	109880	Luo X	Isolation and molecular characterization of circulating melanoma cells.	Cell reports	2014	24
24903021	109880	Cooper ZA	Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.	Cancer immunology research	2014	47
24919155	109880	Viros A	Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.	Nature	2014	25
25624498	109880	Perna D	BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.	Proceedings of the National Academy of Sciences of the United States of America	2015	22
25787767	109880	Hu-Lieskovan S	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.	Science translational medicine	2015	59
25843629	109880	Karreth FA	The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.	Cell	2015	30
25873177	109880	Hirata E	Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.	Cancer cell	2015	45
26343581	109880	Zelenay S	Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.	Cell	2015	54
27096321	109880	Salmon H	Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.	Immunity	2016	30
27135738	109880	Souroullas GP	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.	Nature medicine	2016	13
2110186	110157	Blasi E	Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus.	Journal of neuroimmunology	1990	195
15618521	110157	O'Neill E	Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.	Science	2004	85
21712475	110157	Rai K	Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.	Molecular cancer therapeutics	2011	40
25175012	110157	Zhu L	TSC1 controls macrophage polarization to prevent inflammatory disease.	Nature communications	2014	29
9321394	110279	Skorski T	Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.	The EMBO journal	1997	114
10224280	110279	Li S	The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.	The Journal of experimental medicine	1999	127
12124177	110279	Sattler M	Critical role for Gab2 in transformation by BCR/ABL.	Cancer cell	2002	93
16997913	110279	Kuroda J	Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.	Proceedings of the National Academy of Sciences of the United States of America	2006	106
17601986	110279	Neering SJ	Leukemia stem cells in a genetically defined murine model of blast-crisis CML.	Blood	2007	59
25753579	110279	Zhou Y	Lin28b promotes fetal B lymphopoiesis through the transcription factor Arid3a.	The Journal of experimental medicine	2015	20
11607819	214162	Ayton PM	Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.	Oncogene	2001	115
16862118	214162	Krivtsov AV	Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.	Nature	2006	396
17045204	214162	Somervaille TC	Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia.	Cancer cell	2006	177
18371367	214162	McMahon KA	Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal.	Cell stem cell	2007	83
18977325	214162	Krivtsov AV	H3K79 methylation profiles define murine and human MLL-AF4 leukemias.	Cancer cell	2008	158
20010842	214162	Cierpicki T	Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.	Nature structural and molecular biology	2010	61
20133587	214162	Mi S	Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
20194896	214162	Bursen A	The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.	Blood	2010	46
20818375	214162	Liu H	Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint.	Nature	2010	45
21765021	214162	Lane SW	Differential niche and Wnt requirements during acute myeloid leukemia progression.	Blood	2011	36
21828272	214162	Zuber J	An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.	Genes and development	2011	72
22469984	214162	Shi J	The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.	Oncogene	2013	44
24035353	214162	Guo G	Mapping cellular hierarchy by single-cell analysis of the cell surface repertoire.	Cell stem cell	2013	56
26367796	214162	Fong CY	BET inhibitor resistance emerges from leukaemia stem cells.	Nature	2015	48
26367798	214162	Rathert P	Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.	Nature	2015	45
26440282	214162	Saito Y	AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow.	Cell stem cell	2015	18
